

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number  
**WO 03/092582 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number: PCT/US03/11494
- (22) International Filing Date: 28 April 2003 (28.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/376,480 30 April 2002 (30.04.2002) US  
60/385,704 4 June 2002 (04.06.2002) US  
60/427,752 20 November 2002 (20.11.2002) US
- (71) Applicant (for all designated States except US): **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-3147 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **WILSON, James, M.** [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US). **MEDINA, Maria, Fe, C.** [CA/US]; 2200 Ben Franklin Parkway, W401, Philadelphia, PA 19130 (US). **KOBINGER, Gary** [CA/US]; 2049B Bainbridge Street, Philadelphia, PA 19146 (US).
- (74) Agents: **KODROFF, Cathy, A.** et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHIMERIC EBOLA VIRUS ENVELOPES AND USES THEREFOR

(57) Abstract: Chimeric ebola envelope proteins and uses therefore are described. The chimeric envelope proteins are useful for packaging viral vectors and targeting these vectors in vivo, to lung cells following intratracheal delivery or for delivery of molecules, ex vivo, to macrophages and dendritic cells. In another aspect, also provided herein are immunogenic compositions which contain ebola envelope proteins and uses thereof.

WO 03/092582 A2

## CHIMERIC EBOLA VIRUS ENVELOPES AND USES THEREFOR

## BACKGROUND OF THE INVENTION

5

The invention relates generally to recombinant viruses useful for delivery of transgenes and to antigens useful for generating an immune response to ebola virus.

What is needed is a safe vector useful for delivery of a therapeutic gene to a selected target cell. Further, what is desirable is a vector which can readily transduce  
10 the target cell using procedures in which invasiveness is minimized. Also desired are antigens useful in inducing an immune response to against ebola virus.

## SUMMARY OF THE INVENTION

The present invention provides chimeric ebola envelope proteins.

15

In one embodiment, the chimeric ebola envelope proteins are used to generate a chimeric ebola-pseudotyped virus which delivers a selected molecule to a target cell. In another embodiment, the virus of the invention contains lentiviral or other sources of viral sequences packaged into the chimeric ebola envelope protein of the invention.

20

Advantageously, the recombinant virus of the invention containing the chimeric ebola envelope proteins of the invention minimizes the safety concerns that the packaged virus will form replication competent virus. Further, in certain embodiments, the recombinant virus of the invention is particularly well adapted to delivery to mammalian lung cells, as the transfer virus infects from the apical side, permitting delivery via intracheal administration.

25

In another aspect, the chimeric ebola envelope proteins of the invention are delivered to host cells in a manner that induces an immune response to ebola. In one embodiment, immunogenic compositions are prepared which contain vectors carrying the sequences encoding the chimeric ebola envelope proteins under the control of regulatory sequences which direct expression thereof so that, upon  
30 expression in a host cell, an immune response to ebola virus is induced. In another aspect, an immunogenic composition of the invention contains one or more of the

ebola virus envelope proteins of the invention, wild-type ebola envelope proteins, and/or mixtures thereof in a suitable immunogenic carrier.

These and other aspects of the invention will be readily apparent from the following detailed description of the invention.

5

## BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1A through 1Q are schematic diagrams of chimeric filovirus envelope proteins of the invention based on the ebola Zaire (EboZ) strain glycoprotein. Hybrid envelopes were developed by replacing EboZ transmembrane (Tm) and cytoplasmic (Cyt) domains with corresponding regions from Vesicular Stomatitis Virus glycoprotein (VSV-G). Fig. 1A is a schematic diagram of the wild-type (wt) EboZ glycoprotein [SEQ ID NO:1]. Fig. 1B is a schematic diagram of chimeric eboZ glycoprotein V/TC which is deleted of the eboZ wt Tm and Cyt domains fused to an intact VSV tm domain (amino acids 463 to 511 of SEQ ID NO:3). Fig. 1C is a schematic diagram of chimeric eboZ glycoprotein -2aa, which is deleted of the wt Tm and Cyt domains fused to a shortened version of the VSV transmembrane domain (amino acids 465 to 511 of SEQ ID NO:3) and an intact VSV-G cytoplasmic domain. Fig. 1D is a schematic diagram of chimeric eboZ glycoprotein +2aa, in which the ebola envelope protein deleted of the wt tm and cyt domains is fused to a short sequence of VSV from the sequences 5' to its Tm and Cyt, the Tm and Cyt domain (amino acids 461 to 511 of SEQ ID NO:3). Fig. 1E is a schematic diagram of chimeric eboZ glycoprotein +16aa, which is deleted of the wt Tm and Cyt domains and fused to a longer 5' sequence from VSV-G, the VSV-G Tm domain and the Cyt domain of VSV-G (amino acids 447 to 511 of SEQ ID NO:3). Fig. 1F is a schematic diagram of a chimeric eboZ glycoprotein +23aa, in which the ebola envelope protein is deleted of the transmembrane and cytoplasmic domain and has been fused to a longer 5' sequence from VSV-G, the VSV-G transmembrane domain and the cytoplasmic domain of VSV-G (amino acids 440 to 511 of SEQ ID NO:3). Fig. 1G is a schematic diagram of a chimeric eboZ glycoprotein deleted of the wt tm and cyt domains fused to a VSV Tm domain deleted (hatched) and increased in the 5' region by +42aa to include a putative VSV-G budding domain. Fig. 1H is a

schematic diagram of chimeric ebola V/C, in which the EboZ Tm domain was retained [truncated at amino acid 672, SEQ ID NO:1] and fused to the VSV-G Cyt domain without an intervening EboZ Cyt domain (amino acids 483 to 511 of SEQ ID NO:3). Fig. 1I a schematic diagram of chimeric ebola V/2C, in which the full-length ebola envelope protein is fused to the cytoplasmic domain of VSV-G (amino acids 483 to 511 of SEQ ID NO:3). Fig. 1J is a schematic diagram of chimeric EboZ envelope V/T, in which the ebola protein has a terminal truncation which removed the transmembrane and cytoplasmic domains (terminating at amino acid 650 of SEQ ID NO:1), and which is fused to the transmembrane domain of VSV-G (amino acids 463 to 482 of SEQ ID NO:3). Fig. 1K is a schematic diagram of chimeric EboZ envelope ( $\Delta$ Int), in which a region immediately upstream of the EboZ Tm domain was deleted [truncated at amino acid 629, SEQ ID NO:1] and fused to sequences from VSV-G including the transmembrane and cytoplasmic domains. Fig. 1L is schematic diagram of chimeric EboZ envelope  $\Delta$ Imm, in which a region immediately upstream of the EboZ Tm domain was deleted [truncated at amino acid 563, SEQ ID NO:1] fused to sequences from VSV-G including the transmembrane and cytoplasmic domains. Fig. 1M is a chimeric EboZ envelope which contains the eboZ binding domain cloned in the VSV-G envelope (VE). Fig. 1N is a schematic diagram of chimeric EboZ envelope H/TC, which is composed of the ebola protein with a terminal truncation which removed the transmembrane and cytoplasmic domains (terminating at amino acid 650, SEQ ID NO:1), fused to the transmembrane domain of an HIV glycoprotein (amino acids 661 to 856, SEQ ID NO:8). Fig. 1O is schematic diagram of chimeric EboZ envelope M/C, which is composed of the ebola protein with a terminal truncation that removed the transmembrane and cytoplasmic domains of ebola, with the ebola truncate fused to a VSV-G transmembrane domain and an MLV-GP cytoplasmic domain (amino acids 634 to 649 of MLV-GP, SEQ ID NO:6). Fig. 1P is schematic diagram of chimeric EboZ envelope M/CR, which is composed of the M/C construct with an "R" peptide of MLV-GP (amino acids 650 to 665 of MLV-GP, SEQ ID NO:6). Fig. 1Q is schematic diagram of chimeric EboZ envelope L/TC, which is composed of the ebola protein with a terminal truncation that removed the wild-type transmembrane and cytoplasmic domain; fused to the



terminal truncation is the transmembrane protein and cytoplasmic domain of lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) (amino acids 439 to 498 of LCMV-GP, SEQ ID NO:9).

Figs. 2A through 2O are schematic diagrams of chimeric filovirus envelope proteins of the invention based on the ebola Zaire strain glycoprotein. Fig. 2A is the wild-type EboZ glycoprotein. Fig. 2B is an EboZ deletion chimera created by deleting a region in the carboxy-terminal (Ebo $\Delta$ Cyt) region of the envelope. Fig. 2C is an EboZ deletion chimera created by deleting a region in the amino-terminal (Ebo $\Delta$ N) region of the envelope. Fig. 2D is a chimeric ebola envelope created by removing 130 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD1). Fig. 2E is a chimeric ebola envelope created by removing 135 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD2). Fig. 2F is a chimeric ebola envelope created by removing 121 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD3). Fig. 2G is a chimeric ebola envelope created by removing 185 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD4). Fig. 2H is a chimeric ebola envelope created by removing 209 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD5). Fig. 2I is a chimeric ebola envelope created by removing 217 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD6). Fig. 2J is a chimeric ebola envelope created by removing 229 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD7). Fig. 2K is a chimeric ebola envelope created by removing 238 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD8). Fig. 2L is a chimeric ebola envelope created by removing 256 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD9). Fig. 2M is a chimeric ebola envelope created by removing 270 amino acids from the variable, mucin-rich region located downstream of the EboZ binding domain (NTLD10). Fig. 2N is a schematic drawing of an internally deleted LCMV envelope chimera ( $\Delta$ L1) developed in a similar manner.

Fig. 2O is a schematic drawing of an internally deleted LCMV envelope chimera ( $\Delta$ L2) developed in a similar manner.

Figs. 3A through 3J are schematic diagrams of chimeric envelope proteins of the invention based on the ebola soluble glycoprotein. Fig. 3A is the wild-type EboZ envelope glycoprotein. Fig. 3B is the EboZ soluble glycoprotein. Fig. 3C is the EboZ glycoprotein with an internal deletion at amino acids 367-496 [SEQ ID NO:1] (Ebo $\Delta$ 1). Fig. 3D is the EboZ glycoprotein with an internal deletion at amino acids 367-501 [SEQ ID NO:1] (Ebo $\Delta$ 2). Fig. 3E is the EboZ glycoprotein with an internal deletion at amino acids 367-491 [SEQ ID NO:1] (Ebo $\Delta$ 3). Fig. 3F is the EboZ glycoprotein with an internal deletion at amino acids 312-496 [SEQ ID NO:1] (Ebo $\Delta$ 4). Fig. 3G is the EboZ soluble glycoprotein with a terminal deletion at amino acid 220 [SEQ ID NO:2] (Ebo $\Delta$ 5S). Fig. 3H is the EboZ soluble glycoprotein with a terminal deletion at amino acid 361 [SEQ ID NO:2] (Ebo $\Delta$ 6). Fig. 3I is the EboZ soluble glycoprotein with a terminal deletion at amino acid 628 [SEQ ID NO:2] (Ebo $\Delta$ 7S). Fig. 3J is the EboZ soluble glycoprotein with an internal deletion at amino acids 312-496 [SEQ ID NO:2] (Ebo $\Delta$ 8S).

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides chimeric ebola virus envelope proteins. These proteins are useful in a variety of contexts, including as immunogens for generating an immune response to ebola when expressed *in vivo*.

In one aspect, the invention provides chimeric ebola virus envelope proteins that are useful for inducing an immune response against ebola. Such proteins can be expressed *in vivo*, e.g., following delivery via a viral or other suitable vector. Alternatively, the chimeric ebola virus envelope proteins can be delivered in protein form via a suitable carrier.

Advantageously, the invention includes chimeric ebola proteins that are as immunogenic as the wild-type (wt) envelope. The invention includes ebola chimera which are advantageous as compared to the wt envelope due to its lower cellular toxicity.

The invention further provides a recombinant virus containing a viral minigene in a chimeric ebola virus envelope protein, which is able to efficiently transduce intact airway epithelia *ex vivo* and more importantly *in vivo*. Thus, the viruses of the invention with the chimeric ebola envelope proteins are particularly well suited for delivery of molecules to airway cells, e.g., for treatment of cystic fibrosis. However, the constructs described herein are useful for targeting viral vectors to desired host cells, including lung cells, dendritic cells, and macrophages, among others.

Other advantages and uses of the proteins and viruses of the invention are described below and will readily be apparent to those of skill in the art.

#### I. Chimeric Ebola Proteins

As used herein the term "chimeric ebola protein" includes proteins that contain, at a minimum, a functional ebola envelope protein binding domain. In one embodiment, the ebola envelope protein contains an intact, wild-type binding domain. However, the wild-type binding domain may be altered, so long as it provides a functional ebola binding domain. By "functional" is meant that the ability of the envelope of the chimeric ebola protein of the invention retains the ability to bind to the target of the wild-type ebola binding domain. These chimeric ebola proteins include ebola envelope proteins with internal deletions, N-terminal deletions, COOH-terminal deletions, and combinations of such deletions and/or ebola envelope proteins with, or without, such deletions which are fused to a partner derived from a protein from other viral source, or a non-viral source. These chimeric ebola proteins can further contain other modifications to the protein sequences of the ebola protein, or the sequences expressing such proteins, e.g., to improve expression, yield, purification, or for other reasons. The chimeric ebola proteins of the invention are not limited by the method by which they are produced, which may be any suitable method including, e.g., recombinant means, chemical means, synthetic means, or by other suitable methods known to those of skill in the art. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, New York.

Thus, the invention provides chimeric filovirus envelope proteins. Suitably, the filovirus which provides the sequences encoding the envelope protein or a polypeptide or peptide thereof (e.g., the binding domain) is an Ebola virus, selected from any suitable serotype, e.g., Zaire, Sudan, Reston, or an artificial serotype. Most preferably, the envelope protein is obtained from the ebola glycoprotein. In  
5 filoviruses, the glycoprotein gene is the fourth gene (of seven) from the 3' end of the negative strand RNA genome. Thus, each of the filoviruses contains a type of glycoprotein organization in which a secreted, non-structural protein is expressed in preference to the structural glycoprotein.

10 For purposes of convenience, the amino acid sequences of the Ebola Zaire strain glycoprotein used in the examples are reproduced in SEQ ID NO: 1; and the amino acid sequences of the Ebola Zaire strain S protein used in the examples herein are reproduced in SEQ ID NO: 2. References to the residue number of the ebola glycoproteins correspond to the numbering provided in these sequences. The  
15 invention is not limited to these amino acid sequences.

In the Ebola Zaire (eboZ) strain, the secreted glycoprotein is 50 to 70 kD, and the type 1 transmembrane form encodes a 120- to 150- kD glycoprotein that is incorporated into the virion. The first 295 amino acids of both proteins are identical in the Zaire strain, but the secreted glycoprotein (sGP) contains an additional 60  
20 amino acids and the transmembrane glycoprotein (GP) contains another 381 COOH-terminal amino acid residues [A. Sanchez et al, *J. Virol.*, 72(8):6442-6447 (1998)]. As these two glycoproteins are known to target different cell types, either may be selected, depending upon the target cell. However, as sGP binds to neutrophils, it may not be as desirable as GP, which binds to endothelial cells.

25 The wild-type eboZ envelope protein contains a signal peptide located at about amino acids 1 to 31; a binding domain located at amino acids 180 to 350; a transmembrane domain located at amino acids 650 to 673; and a cytoplasmic domain located at amino acids 673 to 676, SEQ ID NO:1. Similar structural glycoproteins may be readily obtained from the other Ebola viral strains, or from Marburg virus  
30 glycoprotein, which has been described in comparison to the Ebola virus genome [A. Sanchez et al, *Virus. Res.*, 29(3):215-240 (Sept. 1993)].

The sequences encoding the envelope protein may be obtained by any suitable means, including application of genetic engineering techniques to a viral source, chemical synthesis techniques, recombinant production, or combinations thereof. Suitable sources of the desired viral sequences are well known in the art, and include a variety of academic, non-profit, commercial sources, and from electronic databases. The method by which the sequences are obtained is not a limitation of the present invention. The sequences of the ebola glycoprotein are published and are available from a variety of sources, including GenBank and the on-line database at the National Institutes for Health, PubMed nucleotides and proteins. Based upon the information provided herein and what is known to those of skill in the art, one can readily substitute other ebola strain envelope proteins or fragments thereof in chimeric envelope proteins as described herein.

#### A. Chimeric Envelopes with an Internal Deletion

In one embodiment, a chimeric ebola envelope protein of the invention contains one or more internal deletions within the wild-type ebola region between the signal peptide and the binding domain. Such internal deletions can be in the range of about 1, 5, 10, 15, 20, 50, 75 or more amino acids to about 80, 120, 130, 140, or 150 amino acids in length. The precise length of a selected deletion may be readily determined by one of skill in the art, in view of the information provided herein. Additionally, or alternatively, such an internal deletion(s) can include a truncation within the signal peptide and/or the binding domain, with the proviso that a functional binding domain is retained. Suitably, a truncation in the signal peptide may remove all or a portion of the carboxy terminus of the signal peptide and can be involve removal of from about 1, 5, or 10 to 15, 20, 25 or 30 amino acids. Typically, a truncation in the binding domain is minimal (e.g., from about 1 to about 10 amino acids in length), so that the function of the binding domain is retained. Additionally, or alternatively, such an internal deletion(s) can include removal of all or a portion of the ebola transmembrane domain and a portion of the cytoplasmic domain.

In one embodiment, the invention provides chimera containing internal deletions of the EboZ envelope made by deleting the region between the

signal sequence and the binding domain (EboΔN). In one series of envelopes, deletions are performed on the highly variable, mucin-rich, region located in GP<sub>1</sub>. As this region also contains sequences which contribute to the toxicity of the EboZ envelope *in vitro*, these envelopes were referred to as the NTDL (non-toxic, deletion, lung) chimera.

Examples of other internally deleted chimera include, without limitation, NTDL1, that refers to the ebola Z envelope protein [SEQ ID NO:1] with a deletion of amino acids 367 to 496 (i.e., amino acids 1 to 366 fused to 497 to 676); NTLD2, that refers to the ebola envelope protein with a deletion of amino acids 367 to 501 (i.e., amino acids 1 to 366 fused to 502 to 676); NTLD3, that refers to the ebola envelope protein with a deletion of amino acids 371 to 491 (i.e., amino acids 1 to 370 fused to 492 to 676); NTLD4, that refers to the ebola envelope protein with a deletion of amino acids 312 to 496 (i.e., amino acids 1 to 311 fused to 497 to 676). The furin recognition site (RRTRR, aa 497-501 of SEQ ID NO:1) was retained in NTDL1, NTDL3 and NTDL4 to allow post-translational cleavage of these envelopes. In NTDL2, the furin recognition site was also removed, preventing this envelope from being processed into GP<sub>1</sub> and GP<sub>2</sub>. See, Figs. 2A-2G.

Still other examples of internally deleted chimera include, without limitation, NTLD5, that refers to the ebola envelope protein [with reference to SEQ ID NO:1] with a deletion of amino acids 288 to 496 (i.e., amino acids 1 to 287 fused to 497 to 676); NTDL6, that refers to the ebola envelope protein with a deletion of amino acids 280 to 496 (i.e., amino acids 1 to 279 fused to 497 to 676); NTDL7, that refers to the ebola envelope protein with a 229 aa deletion at amino acids 268-496 (i.e., amino acids 1 to 267 fused to 497 to 676); NTDL8, that refers to the ebola envelope protein with a 238 aa deletion at amino acids 259-496 (i.e., amino acids 1 to 258 fused to 497 to 676); NTDL9, that refers to the ebola envelope protein with a deletion at residues 241 to 496; NTDL10, that refers to the ebola envelope protein with a deletion of amino acids 227 to 496 (i.e., amino acids 1 to 232 fused to 497 to 676); NTDL11, that refers to the ebola envelope protein with a deletion at residues 233-496; and NTDL13 refers to the ebola envelope protein with a deletion of amino acids 232-496 (i.e., amino acids 1 to 231 fused to 497 to 676). In yet another

construct, termed  $\Delta N$ , the ebola envelope protein has been deleted of amino acids 32 to 172 of the cytoplasmic domain so that it contains amino acids 1 to 31 fused to 172 to 676 of the EboZ env protein. See, Figs. 2A-O.

Other suitable internal deletions will be readily apparent to one of skill  
5 in the art.

**B. Chimeric Ebola Proteins with an Amino Terminal Deletion  
and/or Carboxy Terminal Truncations**

In another embodiment, a chimeric ebola envelope protein of the invention can have an amino ( $\text{NH}_2$ -) terminal deletion and/or a carboxy ( $\text{COOH}$ -)  
10 terminal truncation in the ebola envelope protein. Amino terminal deletions can involve truncation or removal of the signal peptide. Such deletions can involve removal of from about 1, 5, or 10 amino acids to about 15, 20, 25 or 30 amino acids. In other embodiment, carboxy terminal truncations involve partial or complete removal of the transmembrane domain (about 1, 5, 10, 15 to about 20 to 23 amino  
15 acids), partial or complete removal of the cytoplasmic domain (about 1 to 3 amino acids), or combinations thereof. Additional amino deletions and/or carboxy truncations can be made, with the proviso that a functional ebola envelope binding domain is retained.

Examples of other suitable chimera include, with reference to SEQ ID  
20 NO:2, Ebo $\Delta$ 5S which is truncated at amino acid 220 (removing amino acid 221 to 664 of the wild-type glycoprotein) and is secretable; Ebo $\Delta$ 6S which is truncated at amino acid 361 (removing amino acid 362 to 664 of the wild-type glycoprotein) and is secretable; Ebo $\Delta$ 7S which is truncated at amino acid 628 (removing amino acid 629 to 664 of the wild-type glycoprotein) and is secretable; and Ebo $\Delta$ 8S which has  
25 an internal deletion at amino acids 312 to 496, so that amino acids 1 to 311 are fused to amino acids 497 to 664 of the wild-type glycoprotein, providing a secretable chimeric. These chimera are prepared using conventional techniques. Other chimera may be developed utilizing the secreted (S) protein.

Examples of suitable amino terminal deleted- or carboxy-terminal  
30 truncations are illustrated herein. For example, in the  $\Delta$ cyt construct, the ebola

envelope protein has been deleted of the cytoplasmic domain so that it contains amino acids 1 to 672 of the EboZ env protein [SEQ ID NO:1].

In addition, a chimeric ebola protein of the invention can have an internal deletion and a carboxy terminal truncation, an internal deletion and an amino terminal deletion, or other combinations of deletions and/or truncations.

### C. Chimeric Envelope Fusion Proteins

Optionally, a chimeric ebola envelope of the invention can be used to construct other chimera which are composed of the deleted and/or truncated ebola envelope fused to another proteins, and particularly viral envelope proteins.

Examples of suitable viral envelope proteins include vesicular stomatitis virus glycoprotein (VSV-G) [W.R. Beyer et al, *J. Virol.*, **76**(3):1488-1495 (2002); PubMed Accession No. CAC47944, encoded by AJ318514.1; protein sequence reproduced in SEQ ID NO:3; coding sequences for transmembrane and cytoplasmic domains reproduced in SEQ ID NO:4; coding sequences for 42 amino acids upstream of VSV-G transmembrane domain reproduced in SEQ ID NO:5; murine leukemia virus (MLV) [GenBank Accession No. AA061196; mature peptide coded by AF411814.1; envelope protein reproduced in SEQ ID NO:6 [propeptide gPr81, aa 1-654; signal peptide aa 1-30; mature env surface peptide, gp70, aa31-458; propeptide, aa 459-654; mature p12E protein, aa 459-639; mature R peptide, aa 640-654]; coding sequences for cytoplasmic and R domains reproduced in SEQ ID NO: 7; human immunodeficiency virus (HIV) 1 [GenBank Accession no. NP\_057856; mature peptide coded by NC\_001802.1; reproduced in SEQ ID NO: 8 [gp160, aa 1-856; signal peptide, aa 1-28; mature gp120, aa 29-511; mature gp41, aa 512-856] and lymphocytic choriomeningitis virus (LCMV) [PJ Southern *et al*, *Virol.*, **157**(10):145-155 (1987); GenBank Accession No. P09991; envelope protein reproduced in SEQ ID NO: 9; coding sequences for transmembrane and cytoplasmic domain reproduced in SEQ ID NO: 10. Desirably, the cytoplasmic domains or transmembrane domains of these viral envelope proteins is used in a fusion protein of the invention. Optionally, other proteins, e.g., the R protein of MLV [aa 640-654 of SEQ ID NO:6], can be used in the fusion proteins of the invention. Alternatively, other suitable fusion partners may be readily selected from other viral or non-viral



sources. Optionally, linkers may be inserted between the sequences encoding the ebola envelope protein of the invention and the sequences encoding the fusion partner.

5 EboZ/VSV-G hybrid envelopes were constructed by fusing the amino terminal region of EboZ envelope containing the receptor-binding domain to the carboxy terminal region of VSV-G containing the TM and CYT domains. In these hybrids, the junction of the fused EboZ/VSV-G sequences is located in GP<sub>2</sub>. Still other exemplary chimeric ebo envelopes lack a CYT domain. See, e.g., Figs. 1A-1Q.

10 Optionally, the construct further contains a transmembrane domain which may of an origin heterologous to the ebola binding domain. For example, the transmembrane domain may be from a VSV-G transmembrane domain. Additionally or alternatively, the ebola envelope protein may further contain a cytoplasmic domain which may be heterologous to the ebola binding domain.

However, the invention is not limited to the specifically illustrated chimeric  
15 constructs. Suitable techniques for constructing such proteins are well known to those of skill in the art. See, generally, Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, New York.

## 20 II. Immunization with Chimeric Ebola Proteins

In another aspect, the chimeric ebola envelope proteins of the invention and the sequences encoding them can be used to induce an immune response to ebola virus in a subject. Suitably, the proteins or coding sequences of the invention are delivered to the cells in a manner which presents them favorably for induction of an  
25 antibody response, a cellular immune response, or both. Any of the ebola envelope proteins described herein may be utilized in this aspect of the invention.

In one embodiment, an ebola envelope protein is delivered to the subject in protein form by a non-viral delivery vehicle. For example, liposomes, micelles, gels, multiple antigen complexes can be prepared utilizing the ebola envelope proteins  
30 described herein. A suitable immunogenic amount of the chimeric ebola envelope protein may be readily determined. For example, about 1 µg to 10 mg of protein may

delivered via a suitable carrier. Optionally, the envelope protein of the invention can be conjugated with a polyethylene glycol conjugate according to published techniques. [See, *e.g.*, US Patent 6,399,385 and references cited therein.]

In another embodiment, the sequences encoding a chimeric ebola envelope protein of the invention is delivered to the cell via a vector. As used herein, the term “vector” encompasses any suitable genetic element which delivers the sequences encoding the construct of the invention to a target cell, including, *e.g.*, a plasmid, a transposon, a cosmid, an episome, a virus, or any other suitable molecule. Such vectors can be readily constructed using techniques known to those of skill in the art, utilizing vector elements known to those of skill in the art including, among others, the vector elements described in this application.

In one embodiment, a viral vector is utilized for delivery. Any suitable viral system can be used including, *e.g.*, adenoviruses, poxviruses, and the like. For example, an adenoviral vector can be constructed using conventional techniques, which contains the sequences encoding a chimeric ebola envelope protein of the invention under the control of regulatory sequences that direct its expression in a cell. Suitably, such an adenoviral vector may be derived from any suitable human or non-human adenovirus, including, for example, any of human adenovirus serotypes 1 to 40, any of the chimpanzee adenovirus serotypes (*e.g.*, Pan 9), or other non-human primate or non-human mammalian serotypes which will transduce the selected target cell. Suitable adenoviruses are readily available from the American Type Culture Collection, Manassas, Virginia. Alternatively, another viral or non-viral vector may be selected. Selection of an appropriate vector is not a limitation of the present invention. Appropriate amounts for vector-mediated delivery of the chimeric ebola envelope sequences can be readily determined by one of skill in the art, based on the information provided herein.

The vectors are administered in sufficient amounts to transduce the target cells and to provide a sufficient level of expression to provide an immune response without undue adverse or with medically acceptable physiological effects, which can be determined by those skilled in the medical arts. Conventional and pharmaceutically acceptable routes of administration include, but are not limited to,

direct delivery to the target organ, inhalation, intraocular, intranasal, intravenous, intramuscular, intratracheal, subcutaneous, intradermal, rectal, oral and other parenteral routes of administration. Routes of administration may be combined, if desired, or adjusted depending upon the transgene or the condition. The route of administration primarily will depend on the nature of the condition being treated.

Dosages of the viral vector will depend primarily on factors such as the age, weight and health of the patient, and may thus vary among patients. For example, an effective adult human or veterinary dosage of the viral vector is generally in the range of from about 100  $\mu$ L to about 100 mL of a carrier containing concentrations of from about  $1 \times 10^6$  to about  $1 \times 10^{15}$  particles, about  $1 \times 10^{11}$  to  $1 \times 10^{13}$  particles, or about  $1 \times 10^9$  to  $1 \times 10^{12}$  particles virus. Dosages will range depending upon the size of the animal and the route of administration. For example, a suitable human or veterinary dosage (for about an 80 kg animal) for intramuscular injection is in the range of about  $1 \times 10^9$  to about  $5 \times 10^{12}$  particles per mL, for a single site.

Optionally, multiple sites of administration may be delivered. In another example, a suitable human or veterinary dosage may be in the range of about  $1 \times 10^{11}$  to about  $1 \times 10^{15}$  particles for an oral formulation. One of skill in the art may adjust these doses, depending the route of administration, and the therapeutic or vaccinal application for which the recombinant vector is employed. The levels of expression of the ebola protein, or for an immunogen, the level of circulating antibody, can be monitored to determine the frequency of dosage administration. Yet other methods for determining the timing of frequency of administration will be readily apparent to one of skill in the art.

The vaccinal and immunogenic compositions of the invention are formulated in a suitable delivery vehicle. For example, one suitable carrier includes saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline). Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The selection of the carrier is not a limitation of the present invention.

Optionally, a composition of the invention may be formulated to contain other components, including, e.g. adjuvants, stabilizers, pH adjusters, preservatives

and the like. Suitable exemplary adjuvants include, among others, liposomes, alum, monophosphoryl lipid A, immune-stimulating complexes (ISCOMS), LPS analogs including 3-O-deacylated monophosphoryl lipid A (Ribi Immunochem Research, Inc.; Hamilton, MT), mineral oil and water, aluminum hydroxide, Amphigen, Avirdine, L121/squalene, muramyl peptides, and saponins, such as Quil A, and any biologically active factor, such as cytokine, an interleukin, a chemokine, a ligands, and optimally combinations thereof. Certain of these biologically active factors can be expressed *in vivo*, e.g., via a plasmid or viral vector. For example, such an adjuvant can be administered with a priming DNA vaccine encoding an antigen to enhances the antigen-specific immune response compared with the immune response generated upon priming with a DNA vaccine encoding the antigen only. Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol. Suitable chemical stabilizers include gelatin and albumin. Other suitable components for inclusion in an immunogenic composition of the invention are well known to those of skill in the vaccine art.

The levels of immunity of the selected gene can be monitored to determine the need, if any, for boosters. Following an assessment of antibody titers in the serum, optional booster immunizations may be desired.

In the examples below, experiments that evaluated humoral and cellular immune responses following vaccination of mice with adenoviral vector expressing different deletion chimera of the Ebola envelope glycoprotein of the invention are described. The inventors have found that the wild-type EboGP and an exemplary construct of the invention, the non-toxic deletion chimeric 4 (NTD4), induced substantial T and B cells responses. Similar frequencies of CD8+ T cells secreting INF- $\gamma$  were observed in mice vaccinated with EboGP or NTD4. Serum from vaccinated mice with EboGP or NTD4 inhibited Ebola GP pseudotyped HIV vector mediated transduction with comparable efficiencies. The immune response induced by EboGP or NTD4 protected mice against lethal challenge performed with massive doses of a mouse-adapted strain of Ebola Zaire virus. Interestingly, a single administration of Ad-mediated EboGP or NTD4 fully protected mice against Ebola

as early as 10 days post-vaccination. Thus, the present invention provides constructs useful in inducing an immune response, including a protective immune response, against ebola.

### 5     III.     Recombinant Viruses

          In one embodiment, the invention provides a recombinant virus composed of a viral vector carrying a heterologous molecule which is packaged in a heterologous envelope comprising a chimeric ebola virus envelope protein. Preferably, the envelope in which the viral minigene is packaged is suitably free of envelope protein  
10     from the source of the viral vector carrying the minigene. The chimeric ebola virus envelope proteins are used to target vectors derived from a viral source which is natively non-enveloped, including, without limitation, adenoviruses and adeno-associated viruses. For use in the present invention, the capsid proteins of such viral vectors can be provided with a lipid bilayer using published techniques, onto which  
15     the chimeric ebola envelope proteins of the invention can be engineered. Alternatively, the chimeric ebola envelope proteins of the invention are useful in providing a heterologous envelope to any vector derived from a viral source which natively contain has an envelope, e.g., retroviruses.

          The heterologous molecule carried on the minigene for delivery to a host cell  
20     may be any desired substance including, without limitation, a polypeptide, protein, enzyme, carbohydrate, chemical moiety, or nucleic acid molecule which may include oligonucleotides, RNA, DNA, and/or RNA/DNA hybrids. In one embodiment, the heterologous molecule is a nucleic acid molecule which introduces specific genetic modifications into human chromosomes, e.g., for correction of mutated genes. In  
25     another desirable embodiment, the heterologous molecule comprises a transgene comprising a nucleic acid sequence encoding a desired protein, peptide, polypeptide, enzyme, or another product and regulatory sequences directing transcription and/or translation of the encoded product in a host cell, and which enable expression of the encoded product in the host cell. Suitable products and regulatory sequences are  
30     discussed in more detail below. However, the selection of the heterologous molecule

carried on the minigene and delivered by the viruses of the invention is not a limitation of the present invention.

Methods of producing the viruses of the invention using packaging host cells are described below.

5           A.     *Viral Elements*

Suitable viral elements for packaging into the chimeric envelope proteins of the invention may be readily determined by one of skill in the art. In one embodiment, the viral elements are selected from among lentiviral sources.

1.     Lentiviral Vectors

10           In one embodiment, a lentiviral minigene is pseudotyped into a chimeric envelope protein of the invention. Suitable lentiviral minigenes are described in detail in WO 01/83730, which is incorporated by reference herein. See, also, WO 00/55335 (Sept. 21, 2000); WO 00/08131 (Feb. 17, 2000); WO 00/00600 (Jan. 6, 2000); WO 99/61589 (Dec. 2, 1999).

15           In selecting the lentiviral elements described herein for construction of a lentivirus minigene and pseudotyped lentivirus of the invention, one may readily select sequences from any suitable lentivirus and any suitable lentivirus serotype or strain. Suitable lentiviruses include, for example, human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), caprine  
20 arthritis and encephalitis virus, equine infectious anemia virus, bovine immunodeficiency virus, visna virus, and feline immunodeficiency virus (FIV). The examples provided herein illustrate the use of minigenes derived from HIV and FIV. However, other lentiviruses of human or non-human origin may also be particularly desirable. The sequences used in the constructs of the invention may be derived from  
25 academic, non-profit (e.g., the American Type Culture Collection, Manassas, Virginia) or commercial sources of lentiviruses. Alternatively, the sequences may be produced recombinantly, using genetic engineering techniques, or synthesized using conventional techniques (e.g., G. Barony and R.B. Merrifield, *THE PEPTIDES: ANALYSIS, SYNTHESIS & BIOLOGY*, Academic Press, pp. 3-285 (1980)), with  
30 reference to published viral sequences, including sequences contained in publicly accessible electronic databases. In the following specification, it will be understood

that a reference to lentiviral sequences involves any suitable means of obtaining the referenced sequences.

a. *LTR sequences*

The lentiviral minigene contains a sufficient amount of  
5 lentiviral long terminal repeat (LTR) sequences to permit reverse transcription of the genome, to generate cDNA, and to permit expression of the RNA sequences present in the lentiviral minigene. Suitably, these sequences include both the 5' LTR sequences, which are located at the extreme 5' end of the minigene and the 3' LTR sequences, which are located at the extreme 3' end of the minigene. These LTR  
10 sequences may be intact LTRs native to a selected lentivirus or a cross-reactive lentivirus, or more desirably, may be modified LTRs.

Various modifications to lentivirus LTRs have been described. One particularly desirable modification is a self-inactivating LTR, such as that described in H. Miyoshi et al, *J. Virol.*, 72:8150-8157 (Oct. 1998) for HIV. In these  
15 HIV LTRs, the U3 region of the 5' LTR is replaced with a strong heterologous promoter (e.g., CMV) and a deletion of 133 bp is made in the U3 region of the 3' LTR. Thus, upon reverse transcription, the deletion of the 3' LTR is transferred to the 5' LTR, resulting in transcriptional inactivation of the LTR. The complete nucleotide sequence of HIV is known. See, L. Ratner et al, *Nature*, 313(6000):277-  
20 284 (1985). Yet another suitable modification involves a complete deletion in the U3 region, so that the 5' LTR contains only a strong heterologous promoter, the R region, and the U5 region; and the 3' LTR contains only the R region, which includes a polyA. In yet another embodiment, both the U3 and U5 regions of the 5' LTRs are deleted and the 3' LTRs contain only the R region. These and other suitable  
25 modifications may be readily engineered by one of skill in the art, in HIV and/or in comparable regions of another selected lentivirus.

Optionally, the lentiviral minigene may contain a  $\Psi$  (psi) packaging signal sequence downstream of the 5' lentivirus LTR sequences. Optionally, one or more splice donor sites may be located between the LTR  
30 sequences and immediately upstream of the  $\Psi$  sequence. According to the present invention, the  $\Psi$  sequences may be modified to remove the overlap with the gag

sequences and to improve packaging. For example, a stop codon may be inserted upstream of the gag coding sequence. Other suitable modifications to the  $\Psi$  sequences may be engineered by one of skill in the art. Such modifications are not a limitation of the present invention.

5                               In one suitable embodiment, the lentiviral minigene contains lentiviral Rev responsive element (RRE) sequences located downstream of the LTR and sequences. Suitably, the RRE sequences contain a minimum of about 275 to about 300 nt of the native lentiviral RRE sequences, and more preferably, at least about 400 to about 450 nt of the RRE sequences. Optionally, the RRE sequences  
10 may be substituted by another suitable element which assists in expression of gag/pol and its transportation to the cell nucleus. For example, other suitable sequences may include the CT element of the Manson-Pfizer virus, or the woodchuck hepatitis virus post-regulatory element (WPRE). Alternatively, the sequences encoding gag and gag/pol may be altered such that nuclear localization is modified without altering the  
15 amino acid sequences of the gag and gag/pol polypeptides. Suitable methods will be readily apparent to one of skill in the art.

Optionally, the pseudotyped lentivirus may contain other lentiviral elements, such as are well known in the art, many of which are described below in connection with the lentiviral packaging sequences. However, notably, the  
20 lentivirus minigene lacks the ability to assemble lentiviral envelope protein. Such a lentivirus minigene may contain a portion of the envelope sequences corresponding to the RRE, but lack the other envelope sequences. However, more desirably, the lentivirus minigene lacks the sequences encoding any functional lentiviral envelope protein in order to substantially eliminate the possibility of a recombination event  
25 which results in replication competent virus.

Thus, the lentiviral minigene of the invention contains, at a minimum, lentivirus 5' long terminal repeat (LTR) sequences, (optionally) a psi encapsidation sequence, a molecule for delivery to the host cells, and a functional portion of the lentivirus 3' LTR sequences. Desirably, the minigene further contains  
30 RRE sequences or their functional equivalent.



## 2. *Non-Lentiviral Viral Sources*

The invention further provides viruses containing the chimeric envelope proteins of the invention in which are packaged vectors from non-lentiviral sources carrying the minigenes. Suitable sources of viral vectors include viruses  
5 which natively contain an envelope protein, including, without limitation, retroviruses.

Other sources include viruses which are natively non-enveloped, but which have been modified so as to be conducive to packaging into the envelope proteins of the invention. For example, it may be desirable to modify an  
10 adenovirus or adeno-associated virus capsid protein for packaging into a chimeric envelope protein of the invention. Suitable techniques include providing the capsid protein of such viral vectors with a lipid coating (e.g., a lipid membrane or bilayer) onto which the chimeric envelope protein adheres. These and other techniques for facilitating association of the capsid proteins with envelope proteins are available in  
15 textbooks and the literature.

## 3. *Transgene*

The selected viral vector packaged into chimeric envelope protein of the invention carries the molecule for delivery to the target cells and other necessary regulatory sequences and vector elements. Desirably, the molecule carried  
20 by the minigene is a transgene. The transgene a nucleic acid molecule comprising a nucleic acid sequence, heterologous to the lentiviral sequences, which encodes a protein, peptide, polypeptide, enzyme, or another product of interest and regulatory sequences directing transcription and/or translation of the encoded product in a host cell, and which enable expression of the encoded product in the host cell. The  
25 composition of the transgene depends upon the intended use for the minigene and the virus of the invention.

For example, one type of transgene comprises a reporter or marker sequence which, upon expression, produces a detectable signal. Such reporter or marker sequences include, without limitation, DNA sequences encoding  
30  $\beta$ -lactamase,  $\beta$ -galactosidase (*LacZ*), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase,

membrane bound proteins including, for example, CD2, CD4, CD8, and the influenza hemagglutinin protein, as well as others well known in the art.

Advantageously, high affinity antibodies to such proteins exist or can be made routinely, as can fusion proteins comprising a membrane bound protein appropriately fused to an antigen tag domain from, among others, hemagglutinin or Myc. These sequences, when associated with regulatory elements which drive their expression, provide signals detectable by conventional means. Such conventional means include enzymatic, radiographic, colorimetric, fluorescence or other spectrographic assays, fluorescent activated cell sorting assay and immunological assays, including enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and immunohistochemistry. For example, where the transgene comprises the LacZ gene, the presence of the virus containing the lentiviral minigene is detected by assays for beta-galactosidase activity. Similarly, where the transgene is luciferase, virus may be measured by light production in a luminometer.

However, desirably, the transgene contains a non-marker gene which can be delivered to a cell or an animal via the virus of the invention. The transgene may be selected from a wide variety of gene products useful in biology and medicine, such as proteins, antisense nucleic acids (e.g., RNAs), or catalytic RNAs. The viruses of the invention are useful for delivery of gene products and other molecules which induce an antibody and/or cell-mediated immune response, e.g., for vaccine purposes. Suitable gene products may be readily selected by one of skill in the art from among immunogenic proteins and polypeptides derived from viruses, as well as from prokaryotic and eukaryotic organisms, including unicellular and multicellular parasites. In another alternative, the recombinant viruses of the invention are useful for delivery of a molecule desirable for study.

In one particularly desirable embodiment, the viruses of the invention are useful for therapeutic purposes, including, without limitation, correcting or ameliorating gene deficiencies, wherein normal genes are expressed but at less than normal levels. The viruses may also be used to correct or ameliorate genetic defects wherein a functional gene product is not expressed. A preferred type of transgene contains a sequence encoding a desired therapeutic product for

expression in a host cell. These therapeutic nucleic acid sequences typically encode products which, upon expression, are able to correct or complement an inherited or non-inherited genetic defect, or treat an epigenetic disorder or disease.

Alternatively, where it is desirable to down-regulate protein expression, a dominant  
5 negative mutant or an antisense sequence may be delivered.

The invention includes methods of producing a virus which can be used to correct or ameliorate a gene defect caused by a multi-subunit protein. In certain situations, a different transgene may be used to encode each subunit of the protein. This is desirable when the size of the DNA encoding the protein subunit is  
10 large, e.g., for an immunoglobulin or the platelet-derived growth factor receptor. In order for the cell to produce the multi-subunit protein, a cell would be infected with viruses containing each of the different subunits. Alternatively, different subunits of a protein may be encoded by the same transgene. In this case, a single transgene would include the DNA encoding each of the subunits, with the DNA for each  
15 subunit separated by an internal ribosome entry site (IRES). This is desirable when the size of the DNA encoding each of the subunits is small, such that the total of the DNA encoding the subunits and the IRES is less than nine kilobases. Alternatively, other methods which do not require the use of an IRES may be used for co-expression of proteins. Such other methods may involve the use of a second internal  
20 promoter, an alternative splice signal, or a co- or post-translational proteolytic cleavage strategy, among others which are known to those of skill in the art.

The selection of the transgene sequence, or other molecule carried by a minigene, is not a limitation of this invention. Choice of a transgene sequence is within the skill of the artisan in accordance with the teachings of this  
25 application.

#### 4. *Regulatory Elements*

Design of a transgene or another nucleic acid sequence that requires transcription, translation and/or expression to obtain the desired gene product in cells and hosts may include appropriate sequences that are operably linked  
30 to the coding sequences of interest to promote expression of the encoded product. "Operably linked" sequences include both expression control sequences that are

contiguous with the nucleic acid sequences of interest and expression control sequences that act *in trans* or at a distance to control the nucleic acid sequences of interest.

Expression control sequences include appropriate transcription  
5 initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. A great number of expression control  
10 sequences -- native, constitutive, inducible and/or tissue-specific -- are known in the art and may be utilized to drive expression of the gene, depending upon the type of expression desired. For eukaryotic cells, expression control sequences typically include a promoter, an enhancer, such as one derived from an immunoglobulin gene, SV40, cytomegalovirus, etc., and a polyadenylation sequence which may include  
15 splice donor and acceptor sites. For a lentiviral vector, the polyadenylation (polyA) sequence generally is inserted following the transgene sequences and before the 3' lentivirus LTR sequence. In one embodiment, the minigene carrying the transgene or other molecule contains the polyA from the lentivirus providing the LTR sequences, e.g., HIV. However, another source of polyA may be readily selected for inclusion  
20 in the construct of the invention. In one embodiment, the bovine growth hormone polyA is selected. A minigene of the present invention may also contain an intron, desirably located between the promoter/enhancer sequence and the transgene. One possible intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence. Another element that may be used in the vector is an internal  
25 ribosome entry site (IRES). An IRES sequence is used to produce more than one polypeptide from a single gene transcript. An IRES sequence would be used to produce a protein that contains more than one polypeptide chain. Selection of these and other common vector elements are conventional and many such sequences are available (see, e.g., Sambrook et al, and references cited therein at, for example,  
30 pages 3.18-3.26 and 16.17-16.27 and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1989).

In one embodiment, high-level constitutive expression will be desired. Examples of useful constitutive promoters include, without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) (see, e.g., Boshart et al, *Cell*, 41:521-530 (1985)), the SV40 promoter, the dihydrofolate reductase promoter, the  $\beta$ -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1 promoter (Invitrogen). Inducible promoters, regulated by exogenously supplied compounds, are also useful and include, the zinc-inducible sheep metallothioneine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98/10088); the ecdysone insect promoter (No et al, *Proc. Natl. Acad. Sci. USA*, 93:3346-3351 (1996)), the tetracycline-repressible system (Gossen et al, *Proc. Natl. Acad. Sci. USA*, 89:5547-5551 (1992)), the tetracycline-inducible system (Gossen et al, *Science*, 268:1766-1769 (1995), see also Harvey et al, *Curr. Opin. Chem. Biol.*, 2:512-518 (1998)), the RU486-inducible system (Wang et al, *Nat. Biotech.*, 15:239-243 (1997) and Wang et al, *Gene Ther.*, 4:432-441 (1997)) and the rapamycin-inducible system (Magari et al, *J. Clin. Invest.*, 100:2865-2872 (1997)). Other types of inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.

In another embodiment, the native promoter for the transgene will be used. The native promoter may be preferred when it is desired that expression of the transgene mimic the native expression. The native promoter may be used when expression of the transgene must be regulated temporally or developmentally, in a tissue-specific manner, or in response to specific transcriptional stimuli. In a further embodiment, other native expression control elements, such as enhancer elements, polyadenylation sites or Kozak consensus sequences may also be used to mimic the native expression.

Another embodiment of the transgene includes a transgene operably linked to a tissue-specific promoter. For instance, if expression in skeletal muscle is desired, a promoter active in muscle should be used. These include the promoters

from genes encoding skeletal  $\beta$ -actin, myosin light chain 2A, dystrophin, muscle creatine kinase, as well as synthetic muscle promoters with activities higher than naturally-occurring promoters (see Li et al., *Nat. Biotech.*, **17**:241-245 (1999)).

Examples of promoters that are tissue-specific are known for liver (albumin,

- 5 Miyatake et al. *J. Virol.*, **71**:5124-32 (1997); hepatitis B virus core promoter, Sandig et al., *Gene Ther.*, **3**:1002-9 (1996); alpha-fetoprotein (AFP), Arbuthnot et al., *Hum. Gene Ther.*, **7**:1503-14 (1996)), bone osteocalcin (Stein et al., *Mol. Biol. Rep.*, **24**:185-96 (1997)); bone sialoprotein (Chen et al., *J. Bone Miner. Res.*, **11**:654-64 (1996)), lymphocytes (CD2, Hansal et al., *J. Immunol.*, **161**:1063-8 (1998);
- 10 immunoglobulin heavy chain; T cell receptor chain), neuronal such as neuron-specific enolase (NSE) promoter (Andersen et al. *Cell. Mol. Neurobiol.*, **13**:503-15 (1993)), neurofilament light-chain gene (Piccioli et al., *Proc. Natl. Acad. Sci. USA*, **88**:5611-5 (1991)), and the neuron-specific vgf gene (Piccioli et al., *Neuron*, **15**:373-84 (1995)), among others.

- 15 One of skill in the art can make a selection among these expression control sequences without departing from the scope of this invention. Suitable promoter/enhancer sequences may be selected by one of skill in the art using the guidance provided by this application. Such selection is a routine matter and is not a limitation of the molecule or construct. For instance, one or more expression control
- 20 sequences may be operably linked to the coding sequence of interest, and inserted into the transgene, the minigene, and the virus of the invention. After following one of the methods for packaging the minigene taught in this specification, or as taught in the art, one may infect suitable cells *in vitro* or *in vivo*. The number of copies of the minigene in the cell may be monitored by Southern blotting or quantitative PCR.
- 25 The level of RNA expression may be monitored by Northern blotting or quantitative RT-PCR. The level of expression may be monitored by Western blotting, immunohistochemistry, ELISA, RIA, or tests of the gene product's biological activity. Thus, one may easily assay whether a particular expression control
- 30 sequence is suitable for a specific product encoded by the transgene, and choose the expression control sequence most appropriate. Alternatively, where the molecule for delivery does not require expression, e.g., a carbohydrate, polypeptide, peptide, etc.,

the expression control sequences need not form part of the lentiviral minigene or other molecule.

Suitably, a minigene of the invention is delivered to a host cell for packaging into a virus by any suitable means, e.g., by transfection of the “naked”  
5 DNA molecule comprising the minigene or by a vector which may contain other viral and regulatory elements described above, as well as any other elements commonly found on vectors. As defined above, a “vector” is any suitable vehicle which is capable of delivering the sequences or molecules carried thereon to a cell. Plasmids are particularly desirable for use in this aspect of the invention, although not  
10 required. The selected vector may be delivered by any suitable method, including transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion.

According to the present invention, the minigene is packaged in a chimeric ebola envelope using the methods described herein to form the virus of the  
15 invention.

The inventors have found that deletion chimeric EboZ envelopes that, when used to pseudotype lentiviral vectors as used herein, increased titers up to 15-fold compared to the wild type EboZ envelope have been developed. These chimeric envelopes of the invention are incorporated within lentiviral vector particles with the  
20 same efficiency as the wild type EboZ envelope. Chimeric Ebo-pseudotyped lentiviral vectors with titers up to 1.5 logs higher compared to previous conditions have been produced. As an alternative to HIV-based vectors, lentiviral vector derived from feline immunodeficiency virus (FIV) that does not cause disease in humans, and has not been known to infect humans despite the extensive interaction  
25 of humans with cats have been used. FIV vectors were pseudotyped with either the wild type or the chimeric EboZ envelopes and injected intratracheally into C57Bl/6 mice. Results show that wild type, and more efficiently, chimeric EboZ envelopes were able to direct FIV vector transduction of airway epithelia from the apical side. Thus, chimeric Ebo envelopes of the invention can be used to generate higher titers  
30 of pseudotyped lentiviral vectors, retain the same tropism as the wild type Ebo envelope, allows higher efficiency of transduction of airway cells *in vivo*, while at the

same time possesses minimal Ebo sequences than wild type Ebo envelope. Use of the chimeric envelope constructs of the invention for pseudotyping also provides advantages for large-scale production of these vectors.

5    IV.    Production of Recombinant Virus

The invention further involves a method of producing a recombinant virus useful for delivering a selected molecule to a host cell.

10    In one embodiment, *in vitro* packaging techniques may be utilized, in which the envelope protein is produced in a host cell using the techniques described herein, extracted using conventional protein extraction techniques, and used to package the virus *in vitro*.

15    The nucleic acid molecule carrying the sequences encoding the envelope protein operably linked to its expression control sequences as described above, may be readily selected from among any suitable genetic element (i.e., vector) from which the envelope protein can be expressed in the host cell. However, a plasmid is preferred for this purpose. A suitable expression plasmid may be readily selected by one of skill in the art taking into consideration convenience, the selected expression cells, and the like.

20    The necessary envelope protein sequences and regulatory elements may be readily engineered into the selected vector. The envelope sequences are readily selected from a variety of sources identified above. The regulatory sequences may be readily selected from among the sequences described above in the section discussing regulatory sequences for the transgene. Thus, the nucleic acid molecule carrying the envelope protein contains the envelope sequences described above under the control  
25    of regulatory sequences which direct expression of the envelope protein in a host cell.

30    Conventional techniques may be utilized for construction of the viral minigenes and other nucleic acid molecules of the invention. See, generally, Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratories, Cold Spring Harbor, New York. Once the desired vectors are



engineered, they may be transferred to a host cell for packaging into the viral envelope by any suitable method.

The host cell itself may be selected from any prokaryotic cell, including any bacterial cell, or any eukaryotic cell, including insects, and yeast, among others. In one desirable embodiment, the host cell is selected from among mammalian species, and particularly from among human cell types. Suitable cells include, without limitation, cells such as CHO, BKH, MDCK, and various murine cells, e.g., 10T1/2 and WEHI cells, African green monkey cells, suitable primate cells, e.g., VERO, COS1, COS7, BSC1, BSC 40, and BMT 10, and human cells such as WI38, MRC5, A549, human embryonic retinoblast (HER), human embryonic kidney (HEK), human embryonic lung (HEL), TH1080 cells. Other suitable cells may include NIH3T3 cells (subline of 3T3 cells), HepG2 cells (human liver carcinoma cell line), Saos-2 cells (human osteogenic sarcomas cell line), HuH7 cells or HeLa cells (human carcinoma cell line). In a preferred embodiment, appropriate cells include the human embryonic kidney 293T cells (which express the large T antigen) (ATCC). Neither the selection of the mammalian species providing the cells nor the type of mammalian cell is a limitation of this invention.

Regardless of whether a double transfection or triple transfection technique is utilized, the host cells are cultured according to standard methods. See, e.g., R. J. Wool-Lewis and P. Bates, *J. Virol*, 74(4):3155-3160 (Apr. 1998); see, also, Sambrook et al, cited above. See, also, Kobinger et al, *Nat. Biotech.*, 19:225-230 (March 2001); and WO 01/83730 (November 8, 2001).

Suitable techniques include cDNA, genomic cloning, which is well known and is described in Sambrook et al, cited above, and use of overlapping oligonucleotides in the target sequences, combined with polymerase chain reaction, synthetic methods, and any other suitable methods which provide the desired nucleotide sequence. Introduction of the molecules (as plasmids or another vector element) into the host cell may also be accomplished using techniques known to the skilled artisan and as discussed throughout the specification. In a preferred embodiment, standard transfection techniques are used, e.g., CaPO<sub>4</sub> transfection, transfection using the Effectene™ reagent, or electroporation, and/or infection by

viral vectors into cell lines such as those described above. Each of the desired sequences stably contained within the host cell may be under the control of regulatory elements, such as those discussed above in connection with the transgene. In one particularly suitable embodiment, inducible promoters are selected. For example, for pseudotyped lentiviral production, it may be particularly desirable for gag and pol to be expressed under the control of one or more inducible promoters. However, other suitable regulatory elements may be readily selected by one of skill in the art.

Regardless of the production method utilized, the recombinant viruses of the invention may be readily purified from culture using methods known to those of skill in the art. One suitable method involves ultracentrifugation with or without sucrose or affinity chromatography. Conventional techniques may be used to concentrate the recombinant virus (see, e.g., J. C. Burn et al, *Proc. Natl. Acad. Sci. USA*, **90**:8033-8037 (1993)).

## V. Delivery Of Transgenes Via Chimeric Ebola-Pseudotyped Viruses

### A. *Pharmaceutical Compositions*

The chimeric ebola envelope proteins of the invention, recombinant viruses expressing same, and viruses comprising these capsids, can be readily formulated for delivery. Suitably, the chimeric ebola construct of the invention is suspended in a physiologically compatible carrier for administration to a human or non-human mammalian patient. Suitable carriers may be readily selected by one of skill in the art in view of the indication for which the virus is directed. See, e.g., carriers discussed above in connection with the immunogenic compositions. Optionally, the compositions of the invention may contain, in addition to the construct of the invention and carrier(s), other conventional pharmaceutical ingredients, such as preservatives, or chemical stabilizers, such as are described above in connection with the immunogenic compositions.

The recombinant viruses of the present invention may be formulated in such a manner for a variety of uses including *in vitro* protein and peptide expression, as well as *ex vivo* and *in vivo* gene delivery. Thus, the recombinant

viruses of the invention may be used to deliver a selected transgene or other molecule to a host cell by any suitable means. In one embodiment, the viruses and the cells are mixed *ex vivo* and the infected cells are cultured using conventional methodologies. Such methods are described in more detail below. In another embodiment, viruses  
5 have been deemed suitable for applications in which delivery of a molecule, e.g., a transgene which permits transient expression, is therapeutic (e.g., p53 gene transfer in cancer and VEGF gene transfer in heart diseases). However, the viruses are not limited to use where transient expression is desired. The viruses are useful for a variety of situations in which delivery of a selected molecule is desired.

10 B. *Transgenes and Delivery Methods*

Thus, the invention provides a method of delivering a transgene or other molecule to a human or veterinary patient by transducing the cells of the patient with a recombinant virus with a chimeric ebola according to the invention, optionally in combination with an immunosuppressant or immune suppressing regimen.

15 Alternatively, the chimeric ebola proteins of the invention may be used in a non-viral system for targeting selected molecules to cells having receptors for the ebola binding domain. Suitable molecules may be readily selected from among the transgenes described herein and their products, and from a variety of biologically active compounds, including chemical moieties.

20 The target cells may be transduced *in vivo* or *ex vivo*, taking into consideration such factors as the selection of target cells, the transgene being delivered, and the condition for which the patient is being treated. For example, where the targeted cells are selected from muscle cells, lung cells, liver cells or the like, *in vivo* transduction may be more desirable. However, where the targeted cells  
25 are dendritic cells and/or macrophages, *ex vivo* transduction is preferred.

1. *Therapeutic Products*

Useful therapeutic products encoded by the transgene include hormones and growth and differentiation factors including, without limitation, insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH),  
30 growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular

endothelial growth factor (VEGF), angiopoietins, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), transforming growth factor  $\alpha$  (TGF $\alpha$ ),  
5 platelet-derived growth factor (PDGF), insulin growth factors I and II (IGF-I and IGF-II), any one of the transforming growth factor superfamily, including TGF- $\alpha$ , activins, inhibins, or any of the bone morphogenic proteins (BMP) BMPs 1-15, any one of the heregulin/neuregulin/ARIA/neu differentiation factor (NDF) family of growth factors, nerve growth factor (NGF), brain-derived neurotrophic factor  
10 (BDNF), neurotrophins NT-3 and NT-4/5, ciliary neurotrophic factor (CNTF), glial cell line derived neurotrophic factor (GDNF), neurturin, agrin, any one of the family of semaphorins/collapsins, netrin-1 and netrin-2, hepatocyte growth factor (HGF), ephrins, noggin, sonic hedgehog and tyrosine hydroxylase.

Other useful transgene products include proteins that  
15 regulate the immune system including, without limitation, cytokines and lymphokines such as thrombopoietin (TPO), interleukins (IL) IL-1 through IL-25 (including IL2, IL4, IL12 and IL18), monocyte chemoattractant protein, leukemia inhibitory factor, granulocyte-macrophage colony stimulating factor, Fas ligand, tumor necrosis factors  $\alpha$  and  $\beta$ , interferons  $\alpha$ ,  $\beta$ , and  $\gamma$ , stem cell factor, flk-2/flt3  
20 ligand. Gene products produced by the immune system are also useful in the invention. These include, without limitations, immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II MHC molecules, as well as engineered immunoglobulins and MHC  
25 molecules. Useful gene products also include complement regulatory proteins such as complement regulatory proteins, membrane cofactor protein (MCP), decay accelerating factor (DAF), CR1, CF2 and CD59.

Still other useful gene products include any one of the  
30 receptors for the hormones, growth factors, cytokines, lymphokines, regulatory proteins and immune system proteins. The invention encompasses receptors for cholesterol regulation, including the low density lipoprotein (LDL) receptor, high

density lipoprotein (HDL) receptor, the very low density lipoprotein (VLDL) receptor, and the scavenger receptor. Other suitable gene products include those useful for lipid regulation, including, *e.g.*, apolipoprotein A (and its isoforms, including ApoAI), apolipoprotein E (and its isoforms, including E2, E3, and E4),  
5 ABC1, SRB1, and the scavenger receptor. The invention also encompasses gene products such as members of the steroid hormone receptor superfamily including glucocorticoid receptors and estrogen receptors, Vitamin D receptors and other nuclear receptors. In addition, useful gene products include transcription factors such as *jun*, *fos*, max, mad, serum response factor (SRF), AP-1, AP2, *myb*, MyoD and  
10 myogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C/EBP, SP1, CCAAT-box binding proteins, interferon regulation factor (IRF-1), Wilms tumor protein, ETS-binding protein, STAT, GATA-box binding proteins, *e.g.*, GATA-3, and the forkhead family of winged helix proteins.

15 Other useful gene products include, carbamoyl synthetase I, ornithine transcarbamylase, arginosuccinate synthetase, arginosuccinate lyase, arginase, fumarylacetate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, glucose-6-phosphatase, porphobilinogen deaminase, cystathione beta-synthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-coA  
20 dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin, beta-glucosidase, pyruvate carboxylate, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein, T-protein, a cystic fibrosis transmembrane regulator (CFTR) sequence, and a dystrophin cDNA sequence. Still other useful products include those useful for treatment of hemophilia  
25 A (including Factor VIII and its variants, such as the light chain and heavy chain of the heterodimer and the B-deleted domain; US Patent 6,200,560 and US Patent 6,221,349) and hemophilia B (including Factor IX).

Useful gene products include non-naturally occurring polypeptides, such as chimeric or hybrid polypeptides having a non-naturally  
30 occurring amino acid sequence containing insertions, deletions or amino acid substitutions. For example, single-chain engineered immunoglobulins could be

useful in certain immunocompromised patients. Other types of non-naturally occurring gene sequences include antisense molecules and catalytic nucleic acids, such as ribozymes, which could be used to reduce overexpression of a target.

Reduction and/or modulation of expression of a gene is particularly desirable for treatment of hyperproliferative conditions characterized by hyperproliferating cells, as are cancers and psoriasis. Target polypeptides include those polypeptides which are produced exclusively or at higher levels in hyperproliferative cells as compared to normal cells. Target antigens include polypeptides encoded by oncogenes such as myb, myc, fyn, and the translocation gene bcr/abl, ras, src, P53, neu, trk and EGRF. In addition to oncogene products as target antigens, target polypeptides for anti-cancer treatments and protective regimens include variable regions of antibodies made by B cell lymphomas and variable regions of T cell receptors of T cell lymphomas which, in some embodiments, are also used as target antigens for autoimmune disease. Other tumor-associated polypeptides can be used as target polypeptides such as polypeptides which are found at higher levels in tumor cells including the polypeptide recognized by monoclonal antibody 17-1A and folate binding polypeptides.

Other suitable therapeutic polypeptides and proteins include those which may be useful for treating individuals suffering from autoimmune diseases and disorders by conferring a broad based protective immune response against targets that are associated with autoimmunity including cell receptors and cells which produce "self"-directed antibodies. T cell-mediated autoimmune diseases include Rheumatoid arthritis (RA), multiple sclerosis (MS), Sjögren's syndrome, sarcoidosis, insulin dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease and ulcerative colitis. Each of these diseases is characterized by T cell receptors (TCRs) that bind to endogenous antigens and initiate the inflammatory cascade associated with autoimmune diseases.

## 2. *Immunogenic Transgenes*

In another aspect, the invention provides recombinant viruses with chimeric ebola envelope proteins which contain a transgene encoding a peptide, polypeptide or protein which induces an immune response to a selected immunogen.

5 For example, immunogens may be selected from a variety of viral families. Example of viral families against which an immune response would be desirable include, the picornavirus family, which includes the genera rhinoviruses, which are responsible for about 50% of cases of the common cold; the genera  
10 enteroviruses, which include polioviruses, coxsackieviruses, echoviruses, and human enteroviruses such as hepatitis A virus; and the genera apthoviruses, which are responsible for foot and mouth diseases, primarily in non-human animals. Within the picornavirus family of viruses, target antigens include the VP1, VP2, VP3, VP4, and VPG. Another viral family includes the calcivirus family, which encompasses the Norwalk group of viruses, which are an important causative agent of epidemic  
15 gastroenteritis. Still another viral family desirable for use in targeting antigens for inducing immune responses in humans and non-human animals is the togavirus family, which includes the genera alphavirus, which include Sindbis viruses, Ross River virus, and Venezuelan, Eastern & Western Equine encephalitis, and rubivirus, including Rubella virus. The flaviviridae family includes dengue, yellow  
20 fever, Japanese encephalitis, St. Louis encephalitis and tick borne encephalitis viruses. Other target antigens may be generated from the Hepatitis C or the coronavirus family, which includes a number of non-human viruses such as infectious bronchitis virus (poultry), porcine transmissible gastroenteric virus (pig), porcine hemagglutinating encephalomyelitis virus (pig), feline infectious peritonitis  
25 virus (cats), feline enteric coronavirus (cat), canine coronavirus (dog), and human respiratory coronaviruses, which may cause the common cold and/or non-A, B or C hepatitis. Additionally, a coronavirus is the putative causative agent of sudden acute respiratory syndrome (SARS). Within the coronavirus family, target antigens include the E1 (also called M or matrix protein), E2 (also called S or Spike protein),  
30 E3 (also called HE or hemagglutinin-esterase) glycoprotein (not present in all coronaviruses), or N (nucleocapsid). Still other antigens may be targeted against the

rhabdovirus family, which includes the genera vesiculovirus (e.g., Vesicular Stomatitis Virus), and the general lyssavirus (e.g., rabies). Within the rhabdovirus family, suitable antigens may be derived from the G protein or the N protein. The family filoviridae, which includes hemorrhagic fever viruses such as Marburg and Ebola virus may be a suitable source of antigens. The paramyxovirus family includes parainfluenza Virus Type 1, parainfluenza Virus Type 3, bovine parainfluenza Virus Type 3, rubulavirus (mumps virus, parainfluenza Virus Type 2, parainfluenza virus Type 4, Newcastle disease virus (chickens), rinderpest, morbillivirus, which includes measles and canine distemper, and pneumovirus, which includes respiratory syncytial virus. The influenza virus is classified within the family orthomyxovirus and is a suitable source of antigen (e.g., the HA protein, the N1 protein). The bunyavirus family includes the genera bunyavirus (California encephalitis, La Crosse), phlebovirus (Rift Valley Fever), hantavirus (puremala is a hemahagin fever virus), nairovirus (Nairobi sheep disease) and various unassigned bungaviruses. The arenavirus family provides a source of antigens against LCM and Lassa fever virus. The reovirus family includes the genera reovirus, rotavirus (which causes acute gastroenteritis in children), orbiviruses, and cultivirus (Colorado Tick fever, Lebombo (humans), equine encephalosis, blue tongue). The retrovirus family includes the sub-family oncorivirinal which encompasses such human and veterinary diseases as feline leukemia virus, HTLV I and HTLV II, lentivirinal (which includes HIV, simian immunodeficiency virus, feline immunodeficiency virus, equine infectious anemia virus, and spumavirinal). The papovavirus family includes the sub-family polyomaviruses (BKU and JCU viruses) and the sub-family papillomavirus (associated with cancers or malignant progression of papilloma). The adenovirus family includes viruses (EX, AD7, ARD, O.B.) which cause respiratory disease and/or enteritis. The parvovirus family feline parvovirus (feline enteritis), feline panleucopeniavirus, canine parvovirus, and porcine parvovirus. The herpesvirus family includes the sub-family alphaherpesvirinae, which encompasses the genera simplexvirus (HSV I, HSV II), varicellovirus (pseudorabies, varicella zoster) and the sub-family betaherpesvirinae, which includes the genera cytomegalovirus (HCMV, muromegalovirus) and the sub-family



gammaherpesvirinae, which includes the genera lymphocryptovirus, EBV (Burkitts lymphoma), infectious rhinotracheitis, Marek's disease virus, and rhadinovirus. The poxvirus family includes the sub-family chordopoxvirinae, which encompasses the genera orthopoxvirus (*Variola major* (Smallpox) and *Vaccinia* (Cowpox)),  
 5 parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, and the sub-family entomopoxvirinae. The hepadnavirus family includes the Hepatitis B virus. One unclassified virus which may be suitable source of antigens is the Hepatitis delta virus. Another virus which is a source of antigens is Nipah Virus. Still other viral sources may include avian infectious bursal disease virus and porcine  
 10 respiratory and reproductive syndrome virus. The alphavirus family includes equine arteritis virus and various Encephalitis viruses.

The present invention may also encompass immunogens which are useful to immunize a human or non-human animal against other pathogens including bacteria, fungi, parasitic microorganisms or multicellular parasites which  
 15 infect human and non-human vertebrates, or from a cancer cell or tumor cell. Examples of bacterial pathogens include pathogenic gram-positive cocci include pneumococci; staphylococci (and the toxins produced thereby, e.g., enterotoxin B); and streptococci. Pathogenic gram-negative cocci include meningococcus; gonococcus. Pathogenic enteric gram-negative bacilli include enterobacteriaceae;  
 20 pseudomonas, acinetobacteria and eikenella; melioidosis; salmonella; shigella; haemophilus; moraxella; *H. ducreyi* (which causes chancroid); brucella species (brucellosis); *Francisella tularensis* (which causes tularemia); *Yersinia pestis* (plague) and other yersinia (pasteurella); streptobacillus moniliformis and spirillum; Gram-positive bacilli include listeria monocytogenes; erysipelotheix rhusiopathiae;  
 25 *Corynebacterium diphtheria* (diphtheria); cholera; *B. anthracis* (anthrax); donovanosis (granuloma inguinale); and bartonellosis. Diseases caused by pathogenic anaerobic bacteria include tetanus; botulism (*Clostridium botulinum* and its toxin); *Clostridium perfringens* and its epsilon toxin; other clostridia; tuberculosis; leprosy; and other mycobacteria. Pathogenic spirochetal diseases  
 30 include syphilis; treponematoses: yaws, pinta and endemic syphilis; and leptospirosis. Other infections caused by higher pathogen bacteria and pathogenic

fungi include glanders (*Burkholderia mallei*); actinomycosis; nocardiosis; cryptococcosis, blastomycosis, histoplasmosis and coccidioidomycosis; candidiasis, aspergillosis, and mucormycosis; sporotrichosis; paracoccidioidomycosis, petriellidiosis, torulopsosis, mycetoma and chromomycosis; and dermatophytosis.

- 5 Rickettsial infections include Typhus fever, Rocky Mountain spotted fever, Q fever (*Coxiella burnetti*), and Rickettsialpox. Examples of mycoplasma and chlamydial infections include: mycoplasma pneumoniae; lymphogranuloma venereum; psittacosis; and perinatal chlamydial infections. Pathogenic eukaryotes encompass pathogenic protozoans and helminths and infections produced thereby include:
- 10 amebiasis; malaria; leishmaniasis; trypanosomiasis; toxoplasmosis; *Pneumocystis carinii*; *Trichans*; *Toxoplasma gondii*; babesiosis; giardiasis; trichinosis; filariasis; schistosomiasis; nematodes; trematodes or flukes; and cestode (tapeworm) infections.

Many of these organisms and/or toxins produced thereby have been identified by the Centers for Disease Control [(CDC), Department of Health and

15 Human Services, USA], as agents which have potential for use in biological attacks. For example, some of these biological agents, include, *Bacillus anthracis* (anthrax), *Clostridium botulinum* and its toxin (botulism), *Yersinia pestis* (plague), variola major (smallpox), *Francisella tularensis* (tularemia), and viral hemorrhagic fever, all of which are currently classified as Category A agents; *Coxiella burnetti* (Q fever);

20 *Brucella* species (brucellosis), *Burkholderia mallei* (glanders), *Ricinus communis* and its toxin (ricin toxin), *Clostridium perfringens* and its toxin (epsilon toxin), *Staphylococcus* species and their toxins (enterotoxin B), all of which are currently classified as Category B agents; and Nipah virus and hantaviruses, which are currently classified as Category C agents. In addition, other organisms, which are so

25 classified or differently classified, may be identified and/or used for such a purpose in the future. It will be readily understood that the viral vectors and other constructs described herein are useful to deliver antigens from these organisms, viruses, their toxins or other by-products, which will prevent and/or treat infection or other adverse reactions with these biological agents.

- 30 Administration of the vectors of the invention to deliver immunogens against the variable region of the T cells elicit an immune response

including CTLs to eliminate those T cells. In RA, several specific variable regions of TCRs which are involved in the disease have been characterized. These TCRs include V-3, V-14, and V-17. Thus, delivery of a nucleic acid sequence that encodes at least one of these polypeptides will elicit an immune response that will target T cells involved in RA. In MS, several specific variable regions of TCRs which are involved in the disease have been characterized. These TCRs include V-7 and V-10. Thus, delivery of a nucleic acid sequence that encodes at least one of these polypeptides will elicit an immune response that will target T cells involved in MS. In scleroderma, several specific variable regions of TCRs which are involved in the disease have been characterized. These TCRs include V-6, V-8, V-14 and V-16, V-3C, V-7, V-14, V-15, V-16, V-28 and V-12. Thus, delivery of a nucleic acid molecule that encodes at least one of these polypeptides will elicit an immune response that will target T cells involved in scleroderma.

### 3. *Ex Vivo*

In another embodiment, the viruses of the invention are useful for *ex vivo* transduction of target cells. Generally, *ex vivo* therapy involves removal of a population of cells containing the target cells, transduction of the cells *in vitro*, and then reinfusion of the transduced cells into the human or veterinary patient. Such *ex vivo* transduction is particularly desirable when the target cells are dendritic cells or macrophages and/or when the transgene or other molecule being delivered is highly toxic, e.g., in the case of some genes used in the treatment of cancer. However, one of skill in the art can readily select *ex vivo* therapy according to the invention, taking into consideration such factors as the type of target cells to be delivered, the molecule to be delivered, the condition being treated, the condition of the patient, and the like.

In one embodiment it may be desirable to treat a circulating cancer (e.g., leukemia or lymphoma) by *ex vivo* therapy, by removal of bone marrow cells or peripheral blood T lymphocytes, transduction with the virus of the invention *in vitro*, and re-infusion of the transduced cells. In another embodiment, it may be desirable to treat a solid tumor by surgical removal of tumor cells, *ex vivo* transduction of dendritic cells with the transfer virus of the invention carrying an

antigenic epitope from the excised tumor, and re-infusing the altered dendritic cells to induce specific immunity to the antigen. In yet another embodiment, it may be desirable to treat hypercholesterolemia or hyperlipidemia by removal of liver cells (hepatocytes), transduction of the cells with a vector carrying the LDLr gene or  
5 VLDLr gene in culture, and re-infusion of these cells via the portal vein. Still other suitable conditions for *ex vivo* therapy and other useful transgenes will be apparent to one of skill in the art.

Generally, when used for *ex vivo* therapy, the targeted host cells are infected with  $10^5$  TU to  $10^{10}$  TU transfer viruses for each  $10^1$  to  $10^{10}$  cells in a  
10 population of target cells. However, other suitable *ex vivo* dosing levels may be readily selected by one of skill in the art.

#### 4. *In vivo*

For *in vivo* delivery of the transgenes, any suitable route of administration may be used, including, direct delivery to the target organ, tissue or  
15 site, intranasal, inhalation, intravenous, intramuscular, subcutaneous, intradermal, vaginal, rectal, and oral administration. Routes of administration may be combined within the course of repeated therapy or immunization.

Advantageously, the viruses of the invention are particularly well suited to delivery of transgenes and other molecules to lung cells, as these  
20 viruses infect from the apical site, and thus are suited to intratracheal, intranasal, aerosol [Penn Century Sprayer Device, Penn Century, Philadelphia, PA; US Patent 5,579,578] or other suitable delivery means. Although less desirable, bronchoscopy may also be utilized for delivery. In one particularly desirable embodiment, the virus of the invention is engineered to contain a cystic fibrosis transmembrane  
25 conductance regulator (CFTR) gene which is delivered intratracheally. In another embodiment, it may be desirable to treat a solid tumor by injection of a transfer virus carrying a selected transgene (e.g., IL-2, IL-12, TNF, GM-CSF, herpes simplex virus thymidine-kinase (HS-tk), telomerase, a toxic molecule, a suicide gene, or the like), directly into the tumor. However, the invention is not limited as to selection of  
30 transgene or other molecule, or route of delivery, as discussed above.

Suitable doses of viruses may be readily determined by one of skill in the art, depending upon the condition being treated, the health, age and weight of the veterinary or human patient, and other related factors. However, generally, a suitable dose may be in the range of  $10^3$  to  $10^{18}$ , preferably about  $10^5$  to  $10^{16}$  transducing units (TU) per dose, and most preferably, about  $10^7$  to  $10^9$  TU for an adult human having a weight of about 80 kg. Transducing Units (TU) represents the number of infectious particles and is determined by evaluation of transgene (e.g., lacZ) expression upon infection of target cells (usually 293T cells) with limiting dilution of each virus preparation. This dose may be formulated in a pharmaceutical composition, as described above (e.g., suspended in about 0.01 mL to about 1 mL of a physiologically compatible carrier) and delivered by any suitable means. The dose may be repeated, as needed or desired, daily, weekly, monthly, or at other selected intervals.

An optional method step involves the co-administration to the patient, either concurrently with, or before or after administration of the viral vector, of a suitable amount of a short acting immune modulator. The selected immune modulator is defined herein as an agent capable of inhibiting the formation of neutralizing antibodies directed against the recombinant vector of this invention or capable of inhibiting cytolytic T lymphocyte (CTL) elimination of the vector. The immune modulator may interfere with the interactions between the T helper subsets ( $T_{H1}$  or  $T_{H2}$ ) and B cells to inhibit neutralizing antibody formation. Alternatively, the immune modulator may inhibit the interaction between  $T_{H1}$  cells and CTLs to reduce the occurrence of CTL elimination of the vector. A variety of useful immune modulators and dosages for use of same are disclosed, for example, in Yang *et al.*, *J. Virol.*, **70**(9) (Sept., 1996); International Patent Application No. WO96/12406, published May 2, 1996; and International Patent Application No. PCT/US96/03035, all incorporated herein by reference.

The following examples are provided to illustrate construction and use of the recombinant vectors and compositions of the invention and do not limit the scope thereof. One skilled in the art will appreciate that although specific elements,

reagents and conditions are outlined in the following examples, modifications can be made which are meant to be encompassed by the spirit and scope of the invention.

### Examples

- 5           Several chimeric EboZ envelopes were constructed as described in Example 1. In addition, a modified VSV-G with an insertion spanning the putative EboZ GP receptor binding site; and versions of LCMV-GP envelope deleted of internal sequences are described. Examples of hybrid envelopes constructed are illustrated in Figs. 1A-3J.
- 10           Examples 2 to 6 demonstrate testing of exemplary chimeric envelope protein-pseudotyped viral vectors of the invention. More particularly, to determine whether exemplary chimeric EboZ envelope proteins were expressed in cells and incorporated within vector particles, pseudotyped HIV vector particles were produced by triple transfection of 293T cells with an HIV vector, HIV packaging plasmid, and a
- 15           plasmid expressing one of the modified EboZ envelopes. Vector particles were purified by ultracentrifugation through a sucrose cushion, lysed and used for Western blot analysis. Incorporated envelope was detected by probing with an anti-EboZ polyclonal antibody. A single band corresponding to the expected size (140 kD) was present in all the lysed HIV vector particles pseudotyped with envelopes in which the
- 20           ectodomain was not altered. The size of the band detected by the anti-EboZ antibody was smaller than EboZ GP for each vector pseudotyped in the NTDL series; the observed mobility of the envelopes corresponded to their predicted size. The hybrid envelopes were incorporated at similar or less amounts as the EboZ GP, but most of the deletion chimera were all incorporated in higher amounts with at least 2-fold
- 25           greater efficiency than the EboZ GP. Several deletion chimera have been identified which pseudotyped both HIV and FIV vectors resulting in titers up to 5-fold greater than wtEboZ. An FIV vector pseudotyped with a deleted EboZ envelope could be concentrated to high titers and was able to transduce airway epithelia *in vivo* with high efficiency. Clearly, this vector system is useful for delivering therapeutic genes
- 30           *in vivo* to correct the phenotype of genetic diseases.

Examples 7 to 12 are illustrative of the immunogenic and vaccine uses of exemplary chimeric ebo proteins of the invention.

#### Example 1 - Construction of envelopes

5           The mutations within the EboZ coding region and the development of EboZ/VSV-G hybrid envelopes were performed by PCR site-directed mutagenesis. All envelope constructs were confirmed by sequencing. Plasmids pCB6-EboGP encoding the ebola Zaire (EboZ) envelope [Kobinger G., *et al.*, *Nat. Biotech.* 2001, cited above] and pMD.G encoding the VSV-G envelope [U. Blomer, *et al.*, *J. Virol.*,  
10   71:6641-6649 (1997)] were used as PCR templates.

          The plasmid, pCB-Ebo-GP was constructed using the techniques described in R. J. Wool-Lewis and P. Bates, *J. Virol.*, 74(4):3155-3160 (Apr. 1998). Briefly, the cDNA encoding the Zaire subtype of Ebo-GP was obtained from the Centers for Disease Control and Prevention in the vector pGEM3Zf(-) as a *Bam*HI-*Kpn*I  
15   fragment. The Ebo-GP gene was excised from pGEM3Zf(-), using the *Bam*HI and *Eco*RI restriction enzymes, and cloned into an mammalian expression plasmid pCB6 (purchased commercially) downstream of a human cytomegalovirus promoter to create the plasmid pCB6-Ebo-GP.

          For subsequent cloning steps, EboZ restriction enzyme fragments were  
20   derived from a pCDNA3.1 plasmid that contains the EboZ coding region with a Kozak consensus translation initiation site. This plasmid was created by amplifying the 5' region of EboZ in pCB6-EboGP using a sense primer containing the Kozak sequence (AAGGATCCGCCACCATGGGCGTTACAGGAAT, SEQ ID NO:11) and an antisense primer which binds downstream of the *Cla*I site  
25   (GTCACGACAAACTAGTTT GTCGAC, SEQ ID NO:12). The *Cla*I/*Eco*RI fragment from pCB6-EboGP was then used in a triple ligation with the *Bam*HI/*Cla*I PCR product and the *Eco*RI/*Bam*HI fragment of the pCDNA3.1 expression vector.

          The V/TC, -2aa, +2aa, +16aa, +23aa, V/C and V/2C hybrid envelopes were constructed by amplifying the respective regions of VSV-G using a sense primer that  
30   contains EboZ sequences upstream of the junction of the hybrid, and an antisense primer containing an *Eco*RI site. An antisense primer

(GGGAATTCTTACTTTCCAAGTCGGT, SEQ ID NO:13) was used with the following sense primers for amplification of VSV-G sequences:

- GGATGGAGAAGCTCTATTGCCTCTTTTTT, V/TC, SEQ ID NO:14;
- GGATGGAGAATTGCCTCTTTTTTCTTT, -2aa, SEQ ID NO:15;
- 5 GGATGGAGATGGAAAAGCTCTATTGCC, +2aa, SEQ ID NO:16;
- GGATGGAGATCCAAAAATCCAATCGAG, +16aa, SEQ ID NO:17;
- GGATGGAGATTTTTTGGTGATACTGGG, +23aa, SEQ ID NO:18;
- TGTATATGCCGAGTTGGTATCCATCTT, V/C, SEQ ID NO:19;
- TTTGTCTTTCGAGTTGGTATCCATCTT, V/2C, SEQ ID NO:20;

10

LCMV GP sequences were amplified using:

- GGATGGAGACTTTTGATGTTTTCAACA, SEQ ID NO:21 and
- GGGAATTCTCAGCGTCTTTTCCAGATAG, SEQ ID NO:22 primers.

- 15 MLV GP sequences were amplified using

TGTATATGCCGATTAGTCCAATTTGTTA, SEQ ID NO:23, sense primer with either GGGAATTCTATAGAGCCTGGACCACTGAT, SEQ ID NO:24, or GGGAATTCTATGGCTCGTACTCTATAGGC, SEQ ID NO:25, antisense primers to create the M/C OR M/CR hybrids, respectively.

- 20 The EboZ sequence immediately upstream of the junction was also amplified using a sense primer that binds upstream of the BspHI site and an antisense primer that contains VSV-G sequences downstream of the junction of the hybrid. A sense primer (TGGGACCGGACTGCTGT, SEQ ID NO:26) was used with the following antisense primers for amplification of EboZ sequences:

- 25 AATAGAGCTTCTCCATCCTGTCCACCA, SEQ ID NO:27, V/TC;
- AGAGGCAATTCTCCATCCTGTCCACCA, SEQ ID NO:28, -2aa;
- GCTTTTCCATCTCCATCCTGTCCACCA, SEQ ID NO:29, +2aa;



ATTTTGGATCTCCATCCTGTCCACCA, SEQ ID NO:30, +16aa;  
 ACCAAAAATCTCCATCCTGTCCACCA, SEQ ID NO:31, +23aa;  
 ACCAACTCGGCATATACAGAATAAAGCG, SEQ ID NO:32, V/C;  
 ACCAACTCGAAAGACAAATTTGCATAT, SEQ ID NO: 33, V/2C;  
 5 GACTAATCGGCATATACAGAATAAAGCG, SEQ ID NO: 34, M/C and  
 M/CR;  
 CATCAAAAGTCTCCATCCTGTCCACCA, SEQ ID NO: 35, L/TC.

The overlapping PCR products were used as PCR templates, the subsequent  
 10 PCR products were digested with BspHI/EcoRI, and used in a triple ligation with the  
 BamHI/BspHI pCDNA-EboZ fragment and EcoRI/BamHI fragment of pCDNA3.1.  
 A similar strategy was employed to delete the cytoplasmic domain of EboZ in  $\Delta$ Cyt  
 using the same sense primer that binds upstream of the BspHI site and an antisense  
 primer (TGAATTCCTAGCATATACA-GAATAAAGC, SEQ ID NO:36) that binds  
 15 to the transmembrane domain and contains an EcoRI site. To create the V/T  
 envelope, the EboZ and plasmid sequences from V/TC envelope excluding the  
 cytoplasmic domain was amplified, and the resulting PCR product religated.

To construct the  $\Delta$ int and  $\Delta$ imm envelopes, VSV-G sequences were amplified  
 using the sense primer TTTTTCATGATTTTTTTGGTGATACTGGGC, SEQ ID  
 20 NO:37 ( $\Delta$ Int) or TTTTGGCCAACTTTTT TGGTGATACTGGGC, SEQ ID NO:38  
 ( $\Delta$ Imm) with the antisense primer GGGAATTCTTACTTTCCAAGTC GGT, SEQ  
 ID NO:39. The PCR products were then digested with BspHI/EcoRI ( $\Delta$ Int) or  
 MluNI/EcoRI and ligated to the EcoRI/BamHI fragment of pCDNA3.1 and either the  
 BamHI/BspHI or the BamHI/MluNI pCDNA-EboZ fragment.

25 To create the internally deleted NTDL series of envelopes, PCRs were  
 performed to amplify the regions upstream and downstream of the deletion using  
 overlapping primers. A sense primer (GGACCCGTCTAGTGGCT, SEQ ID NO:40)  
 was used with the following antisense primers to amplify the region upstream of the  
 deletion:

30 AGTTCTTCTTGTTAGATGCGACACTGCAG, SEQ ID NO:41, NTDL1;  
 AATTGCTTCTTGTTAGATGCGACACTGCAG, SEQ ID NO:42, NTDL2;

TGTGATCAGTGTGGCAAGGGTTGTTAG, SEQ ID NO: 43, NTDL3;  
 CGAGTTCTTCTTACAACGTGAAAGACAA, SEQ ID NO:44, NTDL4;  
 AGTTCTTCTCTCCCCGATTGTTGTATC, SEQ ID NO:45, NTDL5;  
 AGTTCTTCTGGGGTTGACCTTCCAAAT, SEQ ID NO:46, NTDL6;  
 5 AGTTCTTCTGCTCCTTTTCCCACTTGT, SEQ ID NO:47, NTDL7;  
 AGTTCTTCTCTCATTGAGCTGGAGCAG, SEQ ID NO:48, NTDL8;  
 AGTTCTTCTGGTCAAATTGTCAACCTC, SEQ ID NO:49, NTDL9; and  
 AGTTCTTCTTCCAAAACCGGTAGCCTG, SEQ ID NO:50, NTDL10.

An antisense primer (AATAGAGCTTTGTCTCCATCCTGTCCACC, SEQ  
 10 ID NO:51) was used with the following sense primers to amplify the region  
 downstream of the deletion:

CATCTAACAAGAAGAACTCGAAGAGAA, SEQ ID NO:52, NTDL1;  
 CATCTAACAGAAGCAATTGTCAATGCTC, SEQ ID NO:53, NTDL2;  
 CTTGCCCACTGATCACAGGCGGGAGA, SEQ ID NO:54, NTDL3;  
 15 CACAGTTGTAAGAAGAACTCGAAGAGAA, SEQ ID NO:55, NTDL4.  
 ATCGGGGAGAGAAGAACTCGAAGAGAA, SEQ ID NO: 56, NTDL5;  
 GTCAACCCCAAGAAGAACTCGAAGAGAA, SEQ ID NO:57, NTDL6;  
 AAAAGGAGCAGAAGAACTCGAAGAGAA, SEQ ID NO:58, NTDL7;  
 CTGAATGAGAGAAGAACTCGAAGAGAA, SEQ ID NO:59, NTDL8;  
 20 AATTTGACCAGAAGAACTCGAAGAGAA, SEQ ID NO:60, NTDL9; and  
 GGTTTTGGAAGAAGAACTCGAAGAGAA, SEQ ID NO:61, NTDL10.

The overlapping PCR products were used as PCR templates, the PCR  
 products were digested with AgeI/BspHI, and used in a triple ligation along with the  
 25 BspHI/EcoRI fragment of EboZ and the EcoRI/AgeI fragment of pCDNA-EboZ.

To create the internally deleted LCMV, regions of the LCMV GP were  
 amplified using either

TTTCTCGAGTTTTCTCACTAGGAGACT, SEQ ID NO:62, or  
 TTTCTCGAGTAGGAGACTTGCAGGCAC, SEQ ID NO:63, sense primers  
 30 containing an *Xho* I site (in italics) with GCAACAGCTGTATTCCC, SEQ ID

NO:64, antisense primer. The PCR products were then cloned within the *Xho* I and *Pst* I sites of the pHCMV-GP (WE-HPI) plasmid expressing the LCMV GP.

Using similar techniques, other constructs of the invention can be generated.

## 5 Example 2 - *In vitro* testing of Chimeric Envelopes

### A. *FIV Vectors*

The pseudotyped FIV vectors were evaluated for production of vector capable of *in vitro* transduction. Plasmids expressing the envelopes were used for co-transfection of 293T cells with the FIV transfer vector pVC-LacZwP encoding  $\beta$ -gal and the packaging plasmid pCFIV $\Delta$ orf2 $\Delta$ vif encoding FIV proteins [JC Johnston  
10 *et al*, *J Virol*, 73:4991-5000 (1999)]. Cotransfections were performed using the CalPhos kit (BD BioSciences Clontech, Palo Alto, CA, US) with a 2:4:1 ratio of packaging, transfer and envelope plasmids. Cell supernatants containing HIV vector particles were collected 48-72 hrs post transfection and filtered with a 0.45 $\mu$ m  
15 syringe filter. Limiting dilutions were then performed on 293T cells grown in 24-well plates.

Western blots were performed on vector particles purified from cell supernatants by centrifugation onto a 20% sucrose cushion at 200,000 x g for 3 hrs at 4°C. Pelleted vector particles were lysed in Laemmli sample buffer and aliquots run  
20 in a 4-15% gradient gel (Bio-Rad Laboratories; Hercules). Protein bands were transferred overnight onto a nitrocellulose filter and probed using the ECL-Plus kit (Amersham Pharmacia Biotech; Piscataway NJ, US) with a polyclonal anti-EboZ rabbit antibody and either a monoclonal anti-p26 mouse antibody or a monoclonal anti-p24 human antibody to detect viral capsid proteins. Primary antibodies were  
25 detected using horseradish peroxidase-conjugated anti-rabbit, anti-mouse and anti-human goat antibodies (Santa Cruz Biotech; Santa Cruz CA, US). Bands were visualized by exposure to film (Kodak Biomax MR; Rochester, NY, US) and quantified using the AlphaImager system (Alpha Innotech Corporation; US).

The observed mobility of the envelopes corresponded to what was  
30 observed for the HIV vector particles. Pseudotyping with the hybrid envelopes

resulted in decreased titers compared to EboZ GP envelope. Again, pseudotyping with the NTDL envelopes resulted in increased titers, reaching a peak with NTDL7.

#### B. *HIV Vector*

Pseudotyped HIV vector particles were produced and analyzed using the same conditions as for the FIV vector. Cell supernatants from the triple transfections of LacZ vectors were titrated by limiting dilution assays on 293T cells evaluating for LacZ transduction. Envelopes were also used for cotransfection with the HIV transfer vector pHxLacZWP [PF Kelly *et al*, *Ann NY Acad Sci* **938**:262-276 (2001); G Wang *et al*, *J Clin Invest.*, **104**:R55-62 (1999)] encoding  $\beta$ -gal and packaging plasmid pCMV 8.2 encoding HIV proteins using similar conditions as for the FIV vector.

The HIV titers obtained from pseudotyping with the EboZ/VSV-G hybrid envelopes were 3-4 logs lower compared to the EboZ GP. Vectors pseudotyped with the  $\Delta$ Int,  $\Delta$ Imm, VE, H/TC, L/TC,  $\Delta$ L1 and  $\Delta$ L2 envelopes resulted in negligible to undetectable titers. Pseudotyping with the Ebo/MLV hybrids (M/C, M/CR) resulted in titers in the range of  $10^3$ - $10^4$  (data not shown). However, pseudotyping with the internally deleted NTDL envelopes resulted in up to 7-fold increase in titer. A corresponding increase in titer was observed the greater the size of the deleted region. The titers reached a maximum value with the NTDL6 envelope for the HIV vector. After this peak, the titers subsequently decreased to the level of the EboZ GP.

Progressive deletions in the EboZ GP from NTDL9 ( $\Delta$ aa241-496 of SEQ ID NO:1) to NTDL10 ( $\Delta$ aa227-496 of SEQ ID NO:1) resulted in very low incorporation of glycoprotein on the vector surface and no detectable transduction in vitro. Sequences critical to EboZ GP protein processing and function were mapped by generating a variety of additional variants. Expanding an internal deletion from aa233-496 (SEQ ID NO:1, NTDL11) to aa232-496 (SEQ ID NO:1, NTDL13) by only one amino acid dropped titers from those observed with EboZ GP to undetectable levels. Amino acid 232 [SEQ ID NO:1] is located at the very end of an alpha helix distal to the variable domain supporting its critical role in envelope assembly or the formation of infectious particles.

### Example 3 - Animal models

Large scale preparations of FIV and HIV vector particles were obtained by  
5 cotransfection of 293T cells using either a 2:4:1 or 1:2:3 ratio of packaging, transfer  
and envelope plasmids. Cell supernatants were collected 72 hrs post transfection,  
filtered through a 0.45µm membrane filter and concentrated by ultracentrifugation at  
141,000 x g for 2 hrs at 4°C. Tracheas of C57BL/6 mice were exposed by a midline  
incision and vector particles were injected using a 30 g needle (Becton Dickinson;  
10 Franklin Lakes, NJ, US) (HIV-EboZ-*lacZ* ( $10^7$ ), HIV-NTDL4-*lacZ* ( $10^7$ ), FIV-EboZ-*lacZ* ( $7 \times 10^7$ ) and FIV-NTDL4-*lacZ* ( $2 \times 10^8$ )). After injection, the subcutaneous  
tissues were sutured closed and the mice maintained in animal facility until necropsy.  
At day 35 following vector administration, animals were sacrificed and the lungs  
were inflated with OCT compound (Sakura Finetek; US). Cryosections (10 µm)  
15 were prepared and stained with X-gal overnight for *lacZ* expression.

### Example 4 - Transduction of Pseudotyped Vectors in Human Tracheal Explants

Small pieces ( $0.5 \text{ cm}^2$ ) are excised from explanted normal or CF  
20 human airways and placed on collagen-coated permeable supports. Tissue can be fed  
from the basolateral surface with media as above. Tissues are infected with 50-100µl  
of highly concentrated EboZ or VSV-G-pseudotyped viruses encoding β-  
galactosidase (β-gal) from the apical surface and incubated for 2-4 h.

Viral titers are determined by limiting dilution on 293T cells. Media  
25 is replaced and the tissue is then submerged in media overnight with replacement  
performed every 12 h. Tissue is fixed in 0.5% glutaraldehyde, stained with X-gal at  
37 for 3-12 h, and processed for paraffin embedding. Chimeric EboZ-pseudotyped  
vector is anticipated to yield staining of the epithelium when incubated in X-gal  
substrate 24 h post-infection).

30

## Example 5 - Intratracheal Delivery of HIV- and FIV-Chimeric Ebo

### A. *Murine Studies*

HIV vectors pseudotyped with the EboZ GP envelope have been shown to transduce airway epithelia directly without any requirement for disruption of tight junctions. To determine whether the NTDL envelopes retained this capability of EboZ GP, concentrated HIV and FIV vector particles ( $1-5 \times 10^8$  TU/ml) pseudotyped with the EboZ GP, the NTDL4 or NTDL6 deletion chimeric were prepared and injected ( $10^7$  TU/animal) intratracheally into C57Bl/6 mice. Mice were sacrificed at day 35 and airway tissues were stained to visualize  $\beta$ -galactosidase ( $\beta$ -gal) production.

Both the NTDL4- and NTDL6-pseudotyped vectors transduced airway epithelia with high efficiency. In particular, the NTDL6-HIV-lacZ vector gave rise to more transduced cells that had higher expression levels. At this dose, the EboZ GP-pseudotyped vector transduced airway cells with the same efficiency as the NTDL-pseudotyped vectors (data not shown).

The advantage of the NTDL vectors was best illustrated *in vivo* following the administration of lower doses of vector ( $10^6$  TU/animal). As expected, only negligible numbers of cells were transduced by vectors pseudotyped with EboZ GP. The HIV and FIV vectors pseudotyped with the NTDL6 envelope transduced significantly more airway cells.

### B. *Non-Human Primate Study*

A panel of EboZ-GP envelope deletion chimera was generated to minimize EboZ-GP associated toxicity and possibly improve vector mediated transduction. The four deletion chimera that showed both reduced cellular toxicity and a significant improvement in transduction efficiency *in vitro* and, *in vivo* in immunocompetent mice was tested. HIV-based vector pseudotyped with the Non-Toxic EboZ-GP Deletion 4 or 6 (NTD4 or NTD6) and encoding for the  $\beta$ -galactosidase reporter gene was evaluated following instillation in the lung of non-human primates (rhesus) and compared to the wild-type EboZ-GP envelope pseudotyped HIV vector. Results indicate that HIV-based vector pseudotyped with the Non-Toxic EboZ-GP Deletion chimeric transduce airway epithelia and

submucosal glands more efficiently than the wild type EboZ-GP pseudotyped vector. Areas of the transduced lung with pseudotyped HIV vector showed section with up to 18% of  $\beta$ -galactosidase positive cells by histochemical staining. Overall, the instilled lobe contained 1 HIV vector genome copy per 800 total lung cells for NTD4 as opposed to 1 genome per 1000 cells for EboZ-GP pseudotyped HIV vector as determined by Taq-Man PCR. Pseudotyped HIV vector genomes were detected by Taq-Man PCR in the spleen and liver of one rhesus suggesting that vector may spread to internal organs possibly due to airway injury during instillation with the bronchoscope.

Overall, this study shows that deletion chimera of the Ebola envelope are less toxic and that in the context of HIV-based vector and transduction efficiency of non-human primate, airway is improved.

#### Example 6 - Production of Recombinant Vector Carrying CFTR Gene

Plasmid HR CFTR (HIV vector containing the CFTR gene) is prepared as follows. CFTR is isolated from AdCBCFTR by a SmaI digestion. Then the SmaI-SmaI CFTR gene is ligated to the pHR backbone in the blunted BamHI/XhoI site by using the Klenow fragment of *E. coli*.

Plasmid pHR'EFGP is produced as described in WO 01/83730, cited above.

Plasmid RM (CMV/gag-pol/RRE packaging constructs, e.g., without tat, rev, vif, vpr, vpu) is generated as follows. A XhoI site is inserted by PCR mutagenesis at position 4389 in pCMV R8.2 to generate pCMV R8.2XheI (+1 corresponds to the first nucleotide of the HIV sequence after the CMV promoter in pCMV R8.2). Then pCMV R8.2XheI is digested with XhoI/AvaI, which removed all regulatory and accessory genes as well as the envelope, and ligated to 399 nucleotides encompassing the RRE. The XhoI-RRE-AvaI fragment is generated by PCR from pCMV R8.2 with primers: oligo 5' XheI (sense): SEQ ID NO:65: 5'-AAT TGA ACC ATC TCG AGT AGC ACC C - 3' and oligo 2' AvaI (anti-sense): SEQ ID NO:66: 5'- CCC ACT CCA TTC CGG ACT CGG GAT TCC ACC TGA -3'

Using these constructs, a transfer virus encoding the wt CFTR gene is produced using the methods described above.

### Example 7 - Vaccination with adenovirus vectors expressing wild type and variant EboZ GP

Human serotype 5 adenovirus (AdHu5) or chimpanzee serotype Pan7  
 5 adenovirus (AdC7) vectors expressing Ebola envelope chimeras were produced for *in vivo* immunization experiments in C57BL/6 mice. Five EboZ variants encoded by AdHu5 or AdC7 were selected and produced to evaluate their relative immunogenicity following an intramuscular Ad injection. The wt Ebo, a soluble Ebo variant which contains a truncation as position 364 of the EboZ glycoprotein, EboΔ1,  
 10 EboΔ2, EboΔ3, EboΔ4, EboΔ5S, EboΔ6S, EboΔ7S and EboΔ8S were evaluated in the initial vaccine studies. The soluble proteins were constructed as described above, for the other variants, and are truncated at the carboxy terminus to remove at least the transmembrane and cytoplasmic domains. See, Figs.

Table

15 Production of Adhu5 or AdC7 Adenoviral vector encoding EboZ variant.

Gene <sup>a</sup>	HuAd5 <sup>a</sup>		AdC7 <sup>b</sup>	
	Titer (VP x 10 <sup>12</sup> /ml)	Total yield (VP x 10 <sup>12</sup> )	Titer (VP x 10 <sup>12</sup> /ml)	Total yield (VP x 10 <sup>12</sup> )
Ebo wt	2.6	12	4.3	43
EboS	4.9	49	4.6	55
EboΔ2	2.1	9	5.8	93
EboΔ3	1.7	8	5.3	95
EboΔ4	3	12	4.1	62

<sup>a</sup>Number of viral particles (per ml or total) produced and amplified from infected 293 cells as established by spectrophotometry reading.

30 Vector was administered intramuscularly (10<sup>11</sup> genome copies/cell) in C57BL/6 mice and the presence of virus neutralizing antibody (VNA) was evaluated 28 days later as a first measure of an immune response generated against the Ebola envelope



glycoprotein. VNA is defined here as serum antibody able to inhibit transduction of HeLa cells mediated by HIV-based vector pseudotyped with the wild-type Ebola envelope.

VNA to the EboZ pseudotypes was detected with AdC7 yielding higher titers than AdHu5. The EboZΔ3 eliciting the highest VNA in terms of the transgene targets (Table).

Table. Neutralizing antibody titers to HIV-EboZ-GFP pseudotypes (reciprocal dilution). N=5 animals/group.

	VNA Titers		
	EboZ wildtype	EboZs	EboZΔ3
AdHu5	12	16	12
AdC7	44	12	140

Example 8 - Study to evaluate the immune response (in mice) against Ebola nuclear protein and Ebola envelope antigens following immunization

Mouse studies to evaluate Ebola envelope proteins and the Ebola nuclear antigen were initiated. These studies evaluated neutralizing antibodies in C57Bl/6 mice injected IM with Adhu5 or a chimpanzee adenovirus Pan-7 vector expressing each of 4 Ebola env constructs. The chimpanzee adenovirus Pan-7 vector is the subject of a co-pending, co-owned application.

A. *Evaluation of CTL from C57Bl/6 mice injected IM with Adhu5 or Pan-7 expressing the Ebola env constructs.*

1. *Challenge experiment in mice with Ebola virus.*

Neutralizing antibody (NAB) responses to the Ebola envelope were analyzed by looking at immunized mouse sera mediated neutralization of a lentiviral (HIV) vector pseudotyped with the several constructs (eEbo, NTD2, NTD3, NTD4) of the Ebola envelope glycoprotein. C57BL/6 or BALB/c mice received a single intramuscular injection of  $5 \times 10^{10}$  particles per mouse of C7 (Ad Pan-7) encoding Ebola envelope variant. Neutralizing antibody was evaluated 30 days post-vaccination. Briefly, Ebola Zaire pseudotyped HIV vector encoding for β-

galactosidase (EboZ-HIV-LacZ) was incubated for 2 hr at 37°C with different dilution of heat inactivated mouse serum. Following the incubation with serum, EboZ-HIV-LacZ was then used to infect HeLa cells for 16 hr at 37°C. Infectivity was revealed by X-gal staining of transduced HeLa cells positive for  $\beta$ -galactosidase.

- 5 Neutralizing titer represent the serum reciprocal dilution where a 50% decrease in the number of  $\beta$ -galactosidase positive blue cells was observed.

Sera were collected 30 days post-immunization, which consisted in a single intramuscular (I.M.) administration of  $5 \times 10^{10}$  particles/animal. Neutralizing antibody to Ebola pseudotyped HIV could be detected from all groups with antibody titers ranging from 20 for Ad-EboZ (Adhu5 expressing EboZ), Ad-NTDL3 (Adhu5 expressing NTDL3) and C7-sEbo (Ad Pan-7 expressing soluble EboZ) to over 130 for C7-NTD3 (Ad Pan-7 expressing soluble NTDL3) and C7-NTD4 (Ad Pan-7 expressing soluble NTDL3). The same immunization strategy in BALB/c mice resulted in lower neutralizing antibody titers for Ad- and C7-NTDL2, and NTDL4.

#### B. Cellular Immune Response

The cellular immune response to the Ebola envelope in C57BL/6 mice was evaluated 8 days after a single I.M. administration of  $5 \times 10^{10}$  particles of C7-LacZ or C7-Ebola envelope variant per animal. Mice were vaccinated I.M. with  $5 \times 10^{10}$  particles of C7 encoding LacZ or Ebola envelope variant. Splenic lymphocytes from immunized mice were collected 8 days post vaccination and stimulated in vitro with feeder cells (splenic lymphocytes from untreated mice infected with human Adenovirus serotype 5 encoding for the wild-type Ebola envelope and irradiated). Standard 5-hr CTL assays were performed using  $^{51}\text{Cr}$ -labeled syngeneic C57 cells transfected with an expressor of EboZ.

A positive MHC-restricted cytotoxic T lymphocyte (CTL) response was observed from all AdPan-7 encoding for Ebola envelope variants with a higher response from NTDL2, NTDL3 or NTDL4 immunized mice. Indeed, effector cells from C7 encoding Ebola envelope variant immunized mice recognized EboZ transfected target cells and gave recall CTL responses up to 30% specific lysis. Less

than 5% lysis was seen with effector cells from naïve or LacZ immunized control mice confirming that lysis was specific for Ebola envelope antigens.

*C. Protection Studies*

The most direct means of evaluating C7 (Ad Pan-7) encoding for the EboZ variants as a successful vaccine in mice was to assess protection against weight loss and death following lethal challenge with mouse adapted Ebola Zaire virus. BALB/c mice were immunized with a single dose of  $5 \times 10^{10}$  particles per animal as performed previously and vaccinated animals were challenged with 200 LD<sub>50</sub> of mouse adapted Ebola Zaire 21 days later. All control mice (vehicle and C7-LacZ) died between day 5 to day 9 post-challenge. In contrast, all vaccinated mice but one, (from the C7-sEbo group), survived the challenge with Ebola Zaire.

Weight loss was observed from mice vaccinated with C7-sEbo from day 4 to day 7. Signs of illness such as pilo-erection and from light to severe lethargy were also noted from mice vaccinated with C7-sEbo, NTDL2 and NTDL3 between day 4 to day 7. Mice immunized with C7-EboZ and C7-NTDL4 did not show sign of illness. Overall, a single dose of C7-EboZ and C7-NTDL4 completely protected immunized mice from illness and death possibly due to a significant T-cell mediated immunity.

**Example 9 – Additional Studies of Immune Response to Ebola Proteins**

Additional studies are performed in which the immunology and efficacy of vaccines expressing the predominant ebola nucleoprotein (NP) are evaluated separately from vaccines expressing optimized glycoprotein (GP). The vaccines will be used at different doses ranging from  $10^7$ - $10^{11}$  particles. The vaccine is initially given intramuscularly and where systemic immunization provides protective immunity, additional experiments will deliver the vaccine by the more convenient oral route. The assays for both routes of immunization are similar. Quantitative T cell responses to NP and GP are measured in C57BL/6 mice using an intracellular cytokine assay with peptides to the mapped epitopes. Antibody responses to GP are measured from ICR (outbred), C57BL/6 and C3H/He mice. A surrogate model for protection from Ebola in which Ad-GP/NP vaccinated mice are challenged

intraperitoneally with a replicating vaccinia virus expressing the vaccine target (i.e., GP or NP) will be used [Arichi, T., *et al.*, *Proc. Natl. Acad. Sci. USA*, **97**:297-302 (2000)]. Efficacy is read out by measuring the resulting replication of the vaccinia construct in ovaries. A positive result requires a minimum of a 4-log diminution of recovered vaccinia. The time course of the T and B cell responses is carefully evaluated to determine how soon after immunization a detectable response occurs and how long it lasts.

Six constructs (i.e., AdHu5, AdC6 and AdC68 expressing either NP or optimized GP) are evaluated in two additional models. The first evaluates protection from lethal doses of a mouse adapted ebola Zaire (EboZ) strain in C57BL/6 mice. This allows correlation of EboZ protection with the surrogate vaccinia model and immunologic readouts of immunity such as CD8<sup>+</sup>T cell frequencies, CTL activity, and VNA. The second model involves immunization studies of rhesus macaques with measures of CD8<sup>+</sup>T cell frequencies and VNA.

A. *Immune responses to EboZ NP and GP in mice*

Vectors based on AdHu5 and/or AdC68 are used to perform pilot experiments for T and B cell assays. For both EboZ NP and GP, CD8<sup>+</sup>T cell frequencies are determined by intracellular cytokine analysis; to facilitate the assays, epitopes are mapped. A number of antibody assays are developed against GP. Finally, several structural variants of GP are evaluated for elicitation of VNA to maximize the resulting neutralizing activity.

1. *T cell responses.*

Animals are immunized with adenoviruses expressing EboZ NP or GP and analyzed for a variety of T cell responses including CTL activity by <sup>51</sup>Cr-release assay and intracellular staining for cytokine production by antigen-specific T cells. C57BL/6 and C3H/He mice are injected intramuscularly with 10<sup>11</sup> particles of the corresponding adenovirus vaccine. Splenocytes are harvested 7-12 days later and mononuclear cells are evaluated for antigen-specific T cells using the intracellular cytokine assay with individual peptides from NP and GP. Initial studies will be performed without re-stimulation.

The specific T cell epitopes are mapped using the following strategy. Splenocytes are divided into multiple aliquots and each one incubated with an individual peptide from a peptide library to NP or GP together with Brefeldin A for 5 hrs at 37°C. The cells are then washed and incubated with FITC label antibody to mouse CD8 and a Cy-labeled antibody to CD4. After 45 min on ice, cells are washed, and following permeabilization, a mixture of PE-labeled antibodies to mouse IFN- $\gamma$ , IL-2 and TNF- $\alpha$  will be added. Antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup>T cells are detected by 3-color flow cytometry. The T cell epitopes in the EboZ GP and NP for both C57BL/6 and C3H/He mice are determined.

It should be pointed out that CD4<sup>+</sup>T cell frequencies are generally lower than those of CD8<sup>+</sup>T cells. Thus, epitopes for this subset may not be defined as readily as for the CD8<sup>+</sup>T cells that undergo more vigorous expansion upon activation. Previous studies have identified the amino acid sequence TELRTFSI [aa 577-584 of SEQ ID NO:1] from EboZ GP as a CD8<sup>+</sup>T cell epitope in C3H mice [Rao, M. *et al.*, *Vaccine*, 17:2991-2998 (1999), and the peptide ZYQVNNLEEIC [SEQ ID NO:67] as a dominant epitope for EboZ NP in C57BL/6 mice (unpublished).

For the subsequent experiments, CD8<sup>+</sup>T cell responses to a given antigen of Ebola will be quantitated by using a pool of those peptides that were shown to carry an epitope (for the mouse haplotype used in the experiment). The same approach will be taken to quantitate CD4<sup>+</sup>T cell responses. This will permit better characterization of the Ebo-specific CD8<sup>+</sup>T cell responses, which are assumed to play a major role in providing protection to challenge. The role of CD4<sup>+</sup>T cells in vaccine-induced protection against Ebola virus infection is less well characterized. The same intracellular cytokine assay used to quantitate CD8<sup>+</sup>T cell responses can evaluate the frequency of antigen specific CD4<sup>+</sup>T cells (simply by adding an antibody to CD4<sup>+</sup> carrying a 3<sup>rd</sup> fluorochrome).

It is possible, although not expected, that the frequency of CD4<sup>+</sup> or CD8<sup>+</sup>T cells is below the limit of detectability (less than 0.1-0.5% of all T cells of a given subset depending on levels of background cytokine production) requiring pre-stimulation before the epitope mapping. As a back-up, the transgene-specific T cells

can be expanded by incubating splenocytes *in vitro* for five days in the presence of a heterologous adenovirus recombinant (i.e., not the same serotype as was used for vaccination) expressing the same transgene at 0.1 pfu/cell. Cells thus expanded will then be re-analyzed by an intracellular cytokine assay as described above.

5                   To confirm that cytokine-producing CD8<sup>+</sup>T cells have lytic activity, splenocytes will be tested in a standard <sup>51</sup>Cr-release assay. Target cells (C47SV for C57Bl/6 effector cells and L929 for C3H/He effectors) are infected for 2 hrs with 10 pfu/cell of a vaccinia virus expressing the protein of interest, labeled for 1 hr with <sup>51</sup>Cr at 37 degrees and washed three times. Target cells (10<sup>4</sup>/well) are co-cultured  
10 with various ratios of effector cells in a total volume of 200 µl in V-bottom 96-well microtiter plates. Target cells infected with a vaccinia virus recombinant and effector cells from mice immunized with an adenoviral vector expressing an unrelated transgene product serve as controls. After 5 hrs incubation at 37°C part of the supernatant are harvested and analyzed in a α-counter to determine percent lysis.

15                   Following identification of the CD8<sup>+</sup>T cell epitopes, an alternative CTL assay can be used. For C57Bl/6 mice, this assay uses the RMA-S cell line which is TAP deficient and thus fails to express stable MHC class I molecules on its surface. Stable expression is achieved upon addition of peptides that bind to MHC class I molecules. For C3H/He mice a similar, although not quite as sensitive, assay  
20 can be conducted using peptide-loaded C3H/He mice. For this assay, 5 x 10<sup>5</sup> RMA-S (or L929) cells are incubated overnight at room temperature in serum-free medium under gentle agitation with 1-5 µg/ml of the epitopic peptides. The next morning, cells are labeled with <sup>51</sup>Cr and then analyzed as target cells for T cell-mediated cytolysis as described above.

25                   Upon oral immunization, T cell frequencies are analyzed both from spleens and from the intraepithelial lymphocyte population of the intestine. This population is harvested as follows. The small intestine is removed from exsanguinated mice and placed into medium containing antibiotics. The intestines are transferred onto moist paper towels and connective tissues and Peyer's Patches removed. Each  
30 intestine is opened longitudinally and washed repeatedly in Petri dishes containing medium to remove fecal matter. The intestines are cut into 1-2 cm pieces and placed

into 125 ml flasks containing a stirring bar and 25 ml medium supplemented with 2% FBS, and antibiotics (gentamycin, streptomycin and ampicillin). Flasks will be incubated for 30 min at 37°C with gentle stirring. The fluid is given through a tea strainer to remove large debris. The tissue is transferred to 50 ml tubes with 15 ml medium, vortexed for 2 min and again poured through a strainer. This step is repeated. The cell supernatants are pooled, washed and resuspended in 80 ml of medium. Cells are passed through a loosely packed 5 ml glass wool column and resuspended in 8 ml of 40% Percoll. This solution will be layered onto 2 ml of 75% Percoll. Tubes will be centrifuged for 20 min at rt. 600-800g (2000rpm). Cells at the interphase between the 40-75% Percoll are collected, washed and used for further experiments. For T cell analysis following oral immunization, antibodies to IL-1 are replaced with those to IL-4 or TGF- $\beta$ , two cytokines that play a dominant role in mucosal immune responses.

## 2. *B cell responses.*

The presence of total antibody to Ebola Zaire glycoprotein envelope is determined as follows. The neutralization assay is performed to assess the potential of serum antibody to block transduction of permissive HeLa cells to HIV-vector coated (i.e., pseudotyped) with the wild-type Ebola envelope glycoprotein [Kobinger, GP., *et al.*, *Nat Biotechnol* 19:225-230 (2001)]. Serum samples are obtained by retroorbital bleeding or at termination of the experiment by heart puncture. Sera are heat inactivated at 56°C for 40 min and stored at -20°C. VNA titers are determined on HeLa cells using an Ebola pseudotyped HIV vector encoding for the  $\beta$ -galactosidase gene product (EboZ-HIV-LacZ) at 1 transducing unit (TU)/cell. Different serum dilutions are incubated with EboZ-HIV-LacZ for 1 hr at 37°C in a final volume of 100  $\mu$ l and then use to transduce HeLa cells previously seeded in a 96 well plate. Data are expressed as neutralization titers, which are the reciprocal of the serum dilution resulting in a 50% reduction in the number of transduced cells. Samples are assayed in serial 2-fold dilutions from 1:20 to 1:1280.

Total antibody to Ebola envelope glycoprotein is measured by enzyme-linked immunoadsorbent assay (ELISA). To prepare antigen for ELISA, EboZ-HIV is purified and concentrated by ultracentrifugation (28K for 2 hr at 4°C in

a Beckman SW28 rotor). Microtiter plates (Dynatech, Vienna, VA) or high-binding RIA/EIA flat bottom plates (Costar) are coated with 50  $\mu$ l/well of antigen at a predetermined optimal dilution (1:500 or 1:1000) in PBS. Plates are incubated at 4°C overnight and then nonspecific binding was blocked by the addition of 200  $\mu$ l/well of 5% powdered nonfat milk in PBS containing 0.02% Tween 20. Test antibodies are diluted in either half-log or fivefold increments. Secondary antibody is horseradish peroxidase (HRPO)-labeled goat anti-mouse IgG antibody and the detector substrates are either 2,2'-azino-di 3-ethylbenzthiazoline sulfonate or 3,3', 5,5',-tetramethylbenzidine (TMB, Kirkgaard and Perry Laboratories). Values are read at 405 nm (ABTS) or 450 nm (TMB). Endpoint titers are defined at OD values >0.2 above the mean OD value obtained with the same dilution of serum from control mice. Isotypes of the antibodies to EboZ are tested using the same ELISA with the Calbiochem Hybridoma Subisotyping (LaJolla, CA) kit with some minor previously described modifications [Xiang, Z., *et al*, *J. Virol.*, 76:2667-2675 (2002)]. Sera is tested at a 1:100 dilution.

The final B cell assay is based on a B cell ELISPOT. Multi screen plates will be screened with purified EboZ GP pseudotyped HIV vectors. Following a series of washes, the plates are incubated with  $10^5$  to  $2 \times 10^6$  lymphocytes per well. Cells will be isolated from spleens and placed in wells at a density of  $10^5$  to  $2 \times 10^6$  cells per well for a duration of four hours. Plates are then washed and spots reflecting antibodies of different subtypes will be visualized using a Calbiochem Hybridoma subisotyping kit.

Upon oral immunization, antibody titers and antibody isotype distribution from vaginal lavage fluids (which can be harvested without sacrificing the animals) is analyzed. Upon euthanasia, B cell frequency is determined from spleen as well as from the interstitial lymphocyte population of the lungs, which will be recovered as follows. Lungs will be collected from exsanguinated mice and transferred to Petri dishes and washed with PBS. Lungs are cut into small pieces and digested in serum-free medium with 50 U/ml of collagenase I, and 66 U/ml RNase free Dnase 1 for 60 min at 37°C. Thereafter, cells are shaken vigorously and large clumps will be allowed to settle for 1-2 min. Cells are transferred into a 15 ml tube.



½ volume of 100% Percoll is added and tubes are vortexed. Cells are underlaid with 2 ml of 70% Percoll and centrifuged for 10 min at 2000 rpm. Cells at the interphase are harvested, washed twice and tested in the ELISPOT assay.

5     **Example 10 - Protective immunity to EboZ with novel simian adenovirus vectors in mice**

          A.     *Characterization of B and T cell responses*

          Each novel adenoviral vaccine is characterized in a number of varying strains. Analysis of T cells is performed in C57BL/6 and C3H/He mice utilizing mapped CD8<sup>+</sup>T cell epitopes. Antibody responses are assessed in these strains as well as the outbred ICR mice which better mimic the genetic diversity seen in human populations. Systemic immunity is achieved by intramuscular injection of the adenoviral vector at doses ranging from 10<sup>7</sup> particles to 10<sup>11</sup> particles per animal. Experiments are performed with constructs that independently express NP and optimized GP. Each group contains 10 animals per time point. The initial studies harvest splenocytes at 10 days and mononuclear cells and are analyzed for T cell frequencies, cytolytic activity using standard Chromium release assays. Both T cell frequency and CTL analysis are performed from cells that have not been restimulated to provide a more quantitative assessment of T cell activation *in vivo*. If the CD8<sup>+</sup>T cell frequencies and CTL activity are undetectable, then restimulation is achieved using a heterologous E1-deleted adenovirus vector expressing the same transgene product or peptides to the mapped epitopes.

          1.     *Characterization of B cell response.*

          C57BL/6, C3H and ICR mice are immunized with the corresponding adenovirus vaccines expressing optimized GP as described above. Serum and splenocytes will be harvested at day 28 for assessment of B cell activation to the EboZ GP. Analysis of GP specific antibodies will utilize the neutralizing assay with pseudotyped lentiviral vector as well as a measure of total anti-EboZ GP using an ELISA assay. The frequency of antigen specific B cells will be determined by ELISPOT in cells harvested from spleen. The distribution of Ig isotypes and the expressing B cells are determined by the ELISA and ELISPOT assays.

2. *Vaccinia virus as a surrogate model for protection.*

This strategy is based on immunization of mice with adenovirus expressing the EboZ antigens and subsequent intraperitoneal challenge with a replicating vaccinia virus that expresses the same transgene product. Vaccinia virus recombinants based on the Copenhagen strain of vaccinia virus are constructed with the Ebo inserts provided following previously described procedures [He, Z., *et al.*, *Virology*, **270**:146-171 (2000)]. The recombinants are expanded, titrated in Tk<sup>-</sup> cells, followed by testing for expression of the Ebo sequences by Western blot or immunoprecipitation.

CTL activity elicited as a result of the vaccine facilitates the clearance of vaccinia virus from the peritoneal cavity. Groups of ten vaccinated or sham-vaccinated animals will be challenged intraperitoneally with 10<sup>6</sup> pfu of the vaccinia virus recombinant expressing the transgene used in the vaccine. Five days later, ovaries are harvested, homogenized, freeze-thawed three times, and the cell-free homogenates are titrated in TK<sup>-</sup> monolayers in 24 well plates as described previously. The expected degree of protection, as determined by vaccinia virus titers in ovaries, is expected to correlate with frequency of CD8<sup>+</sup> T cells to the Ebola antigen. Protective T cell responses should lead to at least a 4-log reduction in quantity of recovered vaccinia virus. Splenocytes of vaccinia virus-challenged mice are tested for frequency of CD8<sup>+</sup> T cells to the Ebola antigen to gain information on the effect of a heterologous boost on the frequency of this T cell population. The result of this surrogate challenge model guides the challenge with the mouse-adapted EboZ virus. These studies are restricted to vaccines and vaccine doses that provide adequate protection against vaccinia virus challenge (reduction of vaccinia virus titers in ovaries >4 logs).

3. *Protection from challenge with a mouse-adapted strain of EboZ.*

A murine model of EboZ infection has been developed through the isolation of a strain of EboZ that has undergone serial passage in the mouse [Bray, M., *et al.*, *J Infect Dis*, **178**:651-661 (1998); Bray, M. (2001), *J Gen Virol*, **82**:1365-1373]. The mouse-adapted EboZ causes a lethal syndrome with some

features similar to that observed in primates. Characterization of this mouse-adapted strain of EboZ revealed only 8 amino acid differences with the wild type parental strain [Volchkov, V.E., *et al.*, *Virol*, 277:147-155 (2000)]. Challenge of guinea pigs and rhesus monkeys with this strain of virus leads to lethal consequences, further  
5 confirming its utility as an authentic model.

In order to evaluate protection, groups of 15 mice are vaccinated intramuscularly with the corresponding simian adenovirus vector expressing either NP or optimized GP. Vector is administered at doses equal to or above those shown to protect against the surrogate challenge. One month later, mice  
10 are transferred into the containment area and challenged by intraperitoneal inoculation with 1000 pfu of mouse-adapted Ebola virus (approximately 30,000 times the dose lethal for 50% of adult mice). In order to measure viral titers, five animals from each group are harvested on day 5 and titers of virus are determined from serum using an Ebola virus plaque assay. The other 10 mice are observed for  
15 the development of disease. The expectation is that 100% of the non-vaccinated animals will die within 7 to 14 days. All surviving animals will be necropsied at day 28.

A number of parameters will be evaluated in the context of these challenge experiments. Initial studies will investigate the protection afforded by  
20 adenoviruses expressing either NP or optimized GP at varying doses. Additional experiments will be performed with equal mixtures of the same serotype adenovirus containing both NP and optimized GP vectors ( $10^9$ ,  $10^{10}$  and  $10^{11}$  particles per vector).

#### 4. *Time course of response.*

25 The time course of T and B cell activation following a single administration of an adenovirus vaccine will be important in assessing both the duration of protection as well as the speed with which protection can be achieved. The latter point is particularly important when considering this vector system as a means to diminish mortality following an attack with the agent and to diminish  
30 secondary infection and spread of the agent. Initial studies utilize C57BL/6 mice immunized intramuscularly and harvested at days 3, 6, 9, 12, 15, 21 and 28 (5

animals per group). Serum and spleen are recovered for antibody and T cell assays. The quantitative measures of T and B cell function are correlated with the response of the animals to intraperitoneal challenge with vaccinia virus which are delivered 1, 2, 4, 7, 14, and 28 days after the vaccine. A subset of time points is analyzed in mice in terms of protection against the murine-adapted strain of EboZ. These experiments address two strategic uses of the vaccine. The first is to quickly immunize a population that is at acute risk such as noninfected individuals in close contact to those who were primarily infected from an attack. In this scenario, animals are challenged 1, 2, 4, 7, 14, and 28 days after the vaccine. The second application is to see if vaccination after exposure minimizes morbidity and mortality. For these experiments, animals are vaccinated 1, 2, 3, 4, and 7 days after challenge with the mouse adopted strain of EboZ. The dose of challenge virus varies from 1000, 100, and 10 pfu. It is hoped that these experiments define the time frame following adenovirus in which a protective response can be assured.

The second issue with respect to the time course of immune activation relates to the production of memory B and T cells. This is assessed in animals immunized and subsequently analyzed at later time points including 3, 6, 9 and 12 months after immunization. In each case, the animals are evaluated for B and T cell responses, clearance of intraperitoneal vaccinia virus infection and protection against mouse-adapted EboZ.

#### 5. *Mechanisms of protection*

The advantage of working in the mouse system is that it provides an opportunity to better define mechanisms of protection. The following experiments are performed in the appropriate challenge models.

The surrogate protection model of vaccinia virus clearance is primarily based on activation of CTL, which limits its utility in further evaluating the relative contribution of cellular versus humoral immunity. However, a model of protection against the murine-adapted strain of EboZ is very useful in addressing some of these issues. Initial experiments are designed to evaluate the relative contribution of T cell responses versus antibody responses. Questions relevant to protection following vaccination with NP center around the role of CD4<sup>+</sup> versus

CD8<sup>+</sup> T cells. This can be better defined by depleting either the CD4<sup>+</sup> or CD8<sup>+</sup> T cell fraction immediately prior to challenge. In groups of 10 animals, mice are immunized and 28 days later treated with either three doses of GK 1.5 antibody which eliminates CD4<sup>+</sup> T cells, 53.6.7 antibody which eliminates CD8<sup>+</sup> T cells, or a combination of both. A control group receives similar quantities of Ig preparation to an irrelevant antigen. Antibodies are injected intraperitoneally three times in a 48-hour interval. Flow cytometry is performed on peripheral blood lymphocytes the day after completion of the regimen to assure depletion of peripheral blood CD4<sup>+</sup> and CD8<sup>+</sup> T cells. One day following the last injection of depleting antibody, animals are relocated and challenged with the mouse-adapted EboZ strain. Protection afforded by adenovirus expressing optimized GP could be provided through T cell or B cell mechanisms. Similar studies of CD4<sup>+</sup> and CD8<sup>+</sup> T cells are performed as described for the NP production studies. To evaluate the contribution of neutralizing antibodies to the protective effect, a separate set of animals receives a prime boost regimen of the adenovirus expressing optimized GP using different serotypes in order to boost the level of VNA. Serum from these animals is obtained and passively transferred into recipient non-immunized animals immediately prior to challenge. In this experiment, control mice receive an equal dose of serum from mice immunized with the same vaccine carrier expressing an unrelated antigen.

20

#### Example 11 - Protective immunity to EboZ in nonhuman primates

During the course of the studies described above, a number of vaccine targets (e.g., NP and optimized GP) are evaluated for induction of immune responses in rodents and protection following challenge in the vaccinia virus model and the mouse-adapted EboZ model

25

Guinea pigs of the inbred strain 13 have been shown to be sensitive to an adapted strain of EboZ demonstrating a substantial viremia, and death due to multi-organ damage between days 8 and 11 following challenge [Ryabchikova, E.I., *et al*, *Curr Top Microbiol Immunol*, 235:145-173 (1999); Connolly, B.M., *et al*, *J Infect Dis* 179 Suppl 1: S203-217 (1999)]. The purpose of the guinea pig studies is to demonstrate some level of efficacy before proceeding to primate studies because the

30

guinea pig model appears more discerning than the mouse challenge model. Animals will be immunized with various doses of the adenovirus vaccine ( $10^9$ ,  $10^{10}$  and  $10^{11}$  particles per injection) and 28 days later challenged with the guinea pig-adapted strain of EboZ. Specifically, the animals are injected subcutaneously with 1000 LD<sub>50</sub> (10<sup>4</sup> pfu) of guinea pig-adapted Mayingh strain Ebola virus. The animals are observed for 28 days and blood is obtained at days 7, 14 and 21 for assessment of viremia using a plaque assay (N=2 per time point). Each group contains 12 animals, with a control group receiving a similar dose of the adenovirus expressing an irrelevant gene.

10       The following experiments will be conducted in rhesus macaques. In each case an experimental group includes 4 animals with 1-2 control animals that receive similar doses of the recombinant virus expressing an irrelevant gene. The vaccine is injected intramuscularly into vasus lateralis in a volume of 1 ml over 2 sites. For all experiments, animals are vaccinated and evaluated for T and B cell responses to the vaccine target prior to consideration for challenge experiments. Briefly, two base-  
15       line blood samples are obtained prior to vaccination for assessment of CD8<sup>+</sup> T cell frequencies and VNA. Similar samples will be derived 10, 20, 30, 60 and 90 days after the vaccine, at which time determination is made whether to consider the animals for challenge.

20       The initial primate experiments evaluate the relative performance of the vectors with the optimized EboZ GP as a target at an intramuscular dose of  $10^{12}$  particles. The vector providing the highest level of protection will be considered the lead candidate. The next set of experiments evaluates the efficacy of different vaccine targets in the context of the lead vector. The three experimental groups  
25       include GP alone, NP alone and GP with NP together, all at a dose of  $10^{12}$  delivered intramuscularly. Currently, the GP/NP based vaccine and will do so unless it is very clear that either GP or NP alone provide little evidence of immunologic and/of clinical efficacy. Thereafter, efficacy is studied at  $10^{10}$ ,  $10^{11}$ , and  $10^{12}$  particles. The final experiment evaluates the ability of the best EboZ based vaccine to cross protect  
30       against lethal challenges of ebola Sudan (EboS) and ebola Ivory Coast (EboIC).

### Example 12 - Cross protection of an Ebola vaccine

To address the issue of cross protection, the vaccinia surrogate challenge model is used. Vaccinia viruses are generated expressing EboS and EboIC GP and NP in much the same way they were developed for EboZ genes. Mice are  
5 immunized with the lead adenoviral vector expressing EboZ GP and/or NP. The animals are challenged with vaccinia viruses expressing one of the following genes: EboZ GP, EboZ NP, EboS GP, EboS NP, EboIC GP, and EboIC NP intraperitoneally as described [Xiang, Z., *J Virol.*, 76:2667-2675 (2002)]. Protection is considered  
10 when the amount of vaccinia virus recovered from homogenates of ovaries is diminished at least 4 logs as a result of the vaccination.

Rhesus macaques are evaluated for cross protection as well. Animals are vaccinated with a control virus or the lead vector candidate expressing EboZ derived NP and GP. Each group of control and vaccinated animals will be challenged with lethal doses of clinical isolates of EboZ, EboS or EboIC.

15

All publications cited in this specification are incorporated herein by reference. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall  
20 within the scope of the appended claims.

What is claimed is:

1. A chimeric ebola envelope protein comprising a functional ebola glycoprotein binding domain fused to a heterologous amino acid sequence.
2. The chimeric ebola envelope protein according to claim 1, wherein said protein contains a wild-type ebola glycoprotein binding domain.
3. The chimeric ebola envelope protein according to claim 1, wherein said heterologous amino acid sequence is an ebola glycoprotein sequence which is non-contiguous with the binding domain in the wild-type ebola.
4. The chimeric ebola envelope protein according to claim 1, wherein said chimeric protein comprises an ebola signal peptide and an ebola binding domain having a deletion in the native ebola region between the signal peptide and the binding domain.
5. The chimeric ebola envelope protein according to claim 4, wherein said chimeric protein comprises a deletion of about 1 to 50 amino acids between the signal peptide and the binding domain.
6. The chimeric ebola envelope protein according to any of claims 1 to 3 or claim 5, wherein said chimeric comprises a deletion of the complete ebola signal peptide or a portion thereof.
7. The chimeric ebola envelope protein according to any of claims 1 to 3, claim 5 or claim 6, wherein said deletion of all or a portion of the carboxy terminus of the signal peptide comprises a deletion of from about 1 to 30 amino acids.



8. The chimeric ebola envelope protein according to any of claims 1 to 7, wherein said chimeric ebola envelope comprises a deletion of all or a portion of the ebola transmembrane.

9. The chimeric ebola envelope protein according to claims 8, wherein the deletion of the ebola transmembrane comprises deletion of about 1 to 23 amino acids.

10. The chimeric ebola envelope protein according to any of claims 1 to 9, wherein said chimeric ebola envelope comprises a deletion of all or a portion of the ebola cytoplasmic domain.

11. The chimeric ebola envelope protein according to claim 10, wherein the deletion of the ebola cytoplasmic domain comprises about 1 to 3 amino acids.

12. The chimeric ebola envelope protein according to any of claims 1 to 7 or claim 10 to 11, said chimeric ebola envelope comprising a transmembrane domain.

13. The chimeric ebola envelope protein according to claim 12, wherein the transmembrane domain is from a heterologous protein.

14. The chimeric ebola envelope protein according to any of claims 1 to 9 or claims 12 to 13, wherein said protein further comprises a cytoplasmic domain.

15. The chimeric ebola envelope protein according to any of claims 1 to 12, wherein said heterologous amino acid sequence from a non-ebola protein.

16. The chimeric ebola envelope protein according to claim 15, wherein the heterologous amino acid sequence is selected from the group consisting of a

Vesicular Stomatitis Virus protein; a human immunodeficiency virus transmembrane domain; a murine leukemia virus; and a Lymphocytic Choriomeningitis virus.

17. The chimeric ebola envelope protein according to claim 1, selected from the group consisting of:

- (a) NTDL1, amino acids 1 to 366 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (b) NTDL2, amino acids 1 to 366 fused to amino acids 502 to 676 of the ebola glycoprotein. SEQ ID NO:1;
- (c) NTDL3, amino acids 1 to 370 fused to amino acids 492 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (d) NTDL4, amino acids 1 to 311 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (e) NTLD5, amino acids 1 to 287 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (f) NTDL6, amino acids 1 to 279 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (g) NTDL7, amino acids 1 to 267 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (h) NTDL8, amino acids 1 to 258 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (i) NTDL9, amino acids 1 to 232 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (j) NTDL11, amino acids 1 to 231 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (k)  $\Delta$ N, amino acids 1 to 31 fused to 172 to 676 of the ebola glycoprotein, SEQ ID NO:1;
- (l) Ebo $\Delta$ 5S, amino acids 1 to 220 of the ebola glycoprotein, SEQ ID NO:2;
- (m) Ebo $\Delta$ 6S, amino acids 1 to 361 of the ebola glycoprotein, SEQ ID NO:2;

- (n) Ebo $\Delta$ 7S, amino acids 1 to 628 of the ebola glycoprotein, SEQ ID NO:2; and
- (o) Ebo $\Delta$ 8S, amino acids 1 to 311 fused to amino acids 497 to 664 of the ebola glycoprotein, SEQ ID NO:2;
- (p) V/TC, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 463 to 511 of SEQ ID NO:3;
- (q) -2aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 465 to 511 of SEQ ID NO:3;
- (r) +2aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 461 to 511 of SEQ ID NO:3;
- (s) +16aa, amino acids 1 to 672 of SEQ ID NO:1 fused amino acids 447 to 511 of SEQ ID NO:3;
- (t) +23aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 440 to 511 of SEQ ID NO:3;
- (u) +42aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 421 to 511 of SEQ ID NO:3;
- (v) V/C, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 483 to 511 of SEQ ID NO:3;
- (w) V/2C, amino acids 1 to 676 of SEQ ID NO:1 fused to amino acids 483 to 511 of SEQ ID NO:3;
- (x) V/T, amino acids 1 to 650 of SEQ ID NO:1 fused to amino acids 463 to 482 of SEQ ID NO:3;
- (y)  $\Delta$ Int, amino acids 1 to 629 of SEQ ID NO:1 fused to amino acids sequences 463 to 511 of SEQ ID NO:3;
- (z)  $\Delta$ Imm, amino acids 1 to 563 of SEQ ID NO:1 fused to amino acids 463 to 511 of SEQ ID NO:3;
- (aa) VE, amino acids 180 to 350 of SEQ ID NO:1 in the VSV-G envelope, SEQ ID NO:3.
- (ab) H/TC, amino acids 1 to 650 of SEQ ID NO:1 fused to amino acids 661 to 856, SEQ ID NO:8;

(ac) M/C, amino acids 1 to 650 of SEQ ID NO:1 fused to a VSV-G transmembrane domain, 465 to 482 of SEQ ID NO:3, and an MLV-GP cytoplasmic domain, amino acids 634 to 649 of SEQ ID NO:6;

(ad) M/CR, amino acids 1 to 650 of SEQ ID NO:1 fused to a VSV-G transmembrane domain, 465 to 482 of SEQ ID NO:3, an MLV-GP cytoplasmic domain, amino acids 634 to 649 of SEQ ID NO:6, and an R peptide of MLV-GP, amino acids 650 to 665 of MLV-GP, SEQ ID NO:6;

(ae) L/TC, amino acids 1 to 650 of SEQ ID NO:1, fused to amino acids 439 to 498 of LCMV-GP, SEQ ID NO:9.

18. A nucleic acid molecule encoding a chimeric ebola protein according to any of claims 1 to 17.
19. The molecule according to claim 18, wherein said molecule is a plasmid.
20. The molecule according to claim 18, wherein said molecule is a viral vector.
21. The molecule according to claim 18, wherein said molecule is an adenoviral vector.
22. A host cell comprising a protein according to any of claims 1 to 17 or a molecule according to any of claims 18 to 21.
23. A method of inducing an immune response against ebola comprising the step of delivering to a subject a composition comprising a protein according to any of claims 1 to 17 or a molecule according to any of claims 18 to 21.
24. The method according to claim 23, wherein said composition is delivered intramuscularly.

25. The method according to claim 23, wherein said composition is delivered orally.

26. A recombinant virus having a chimeric ebola envelope protein according to any of claims 1 to 17 and a minigene.

27. The recombinant virus according to claim 26, wherein said minigene is a lentivirus minigene comprising Rev response element (RRE) sequences.

28. The recombinant virus according to claim 26, wherein said lentivirus sequences are selected from the group consisting of a human immunodeficiency virus (HIV) vector, simian immunodeficiency virus (SIV) vector, caprine arthritis and encephalitis virus, equine infectious anemia virus, visna virus, and feline immunodeficiency virus (FIV) vector.

29. The recombinant virus according to claim 28, wherein said lentivirus is an HIV.

30. The recombinant virus according to claim 28, wherein said 5' LTR sequences are self-inactivating.

31. The recombinant virus according to claim 30, wherein said 5' LTR sequences contain a deletion in the U3 region.

32. The recombinant virus according to claim 28, wherein said 3' LTR sequences are self-inactivating.

33. The recombinant virus according to claim 32, wherein said 3' LTR sequences contain a deletion in the U3 region.

34. A host cell containing a recombinant virus according to any of claims 26 to 33.

35. A method of treating a patient with a selected molecule, said method comprising the step of transducing the cells of the patient with the recombinant virus according to any of claims 26 to 33.

36. The method according to claim 35, wherein the cells are selected from among the lung cells, dendritic cells and macrophages.

37. The method according to claim 35, wherein said recombinant virus is administered directly to the patient.

38. The method according to claim 36, wherein the transgene is a CFTR gene and said recombinant virus is administered intratracheally.

39. The method according to claim 35, wherein the cells of the patient are transduced ex vivo, further comprising the step of re-infusing the transduced cells into the patient.

40. The method according to claim 39, wherein the patient is a cancer patient.

41. The method according to claim 39, wherein the transduced cells are dendritic cells.

42. The method according to claim 40, wherein the transduced cells are macrophages.

43. Use of a recombinant virus according to any of claims 26 to 33 in preparing a medicament.











44. A method of delivering a molecule to the apical cells of the lung, said method comprising the step of administering a recombinant virus according to any of claims 26 to 33 intratracheally.

45. An immunogenic composition comprising a DNA molecule encoding a chimeric ebola envelope protein according to any of claims 1 to 17 under the control of sequences which direct expression thereof in a host cell and a carrier.













46. The immunogenic composition according to claim 45 comprising a recombinant virus comprising the DNA molecule.

47. An immunogenic composition comprising an ebola envelope protein and a carrier, wherein said composition comprises an ebola envelope protein according to any of claims 1 to 17.





48. The immunogenic composition according to claim 47, wherein the immunogenic composition further comprises a wild-type ebola G or S protein.







3/3



## SEQUENCE LISTING

<110> The Trustees of the University of Pennsylvania  
 Wilson, James M.  
 Medina, Maria Fe C.  
 Kobinger, Gary

<120> Chimeric Ebola Virus Envelopes and Uses Therefor

<130> UPN-02811PCT

<150> US 60/376,480

<151> 2002-04-30

<150> US 60/385,704

<151> 2002-06-04

<150> US 60/427,752

<151> 2002-11-20

<160> 67

<170> PatentIn version 3.2

<210> 1

<211> 676

<212> PRT

<213> Ebola virus

<400> 1

Met Gly Val Thr Gly Ile Leu Gln Leu Pro Arg Asp Arg Phe Lys Arg  
 1 5 10 15

Thr Ser Phe Phe Leu Trp Val Ile Ile Leu Phe Gln Arg Thr Phe Ser  
 20 25 30

Ile Pro Leu Gly Val Ile His Asn Ser Thr Leu Gln Val Ser Asp Val  
 35 40 45

Asp Lys Leu Val Cys Arg Asp Lys Leu Ser Ser Thr Asn Gln Leu Arg  
 50 55 60

Ser Val Gly Leu Asn Leu Glu Gly Asn Gly Val Ala Thr Asp Val Pro  
 65 70 75 80

Ser Ala Thr Lys Arg Trp Gly Phe Arg Ser Gly Val Pro Pro Lys Val  
 85 90 95

Val Asn Tyr Glu Ala Gly Glu Trp Ala Glu Asn Cys Tyr Asn Leu Glu  
 100 105 110

Ile Lys Lys Pro Asp Gly Ser Glu Cys Leu Pro Ala Ala Pro Asp Gly  
 115 120 125

Ile Arg Gly Phe Pro Arg Cys Arg Tyr Val His Lys Val Ser Gly Thr  
 130 135 140

Gly Pro Cys Ala Gly Asp Phe Ala Phe His Lys Glu Gly Ala Phe Phe  
 145 150 155 160

Leu Tyr Asp Arg Leu Ala Ser Thr Val Ile Tyr Arg Gly Thr Thr Phe  
 165 170 175

Ala Glu Gly Val Val Ala Phe Leu Ile Leu Pro Gln Ala Lys Lys Asp  
 180 185 190

Phe Phe Ser Ser His Pro Leu Arg Glu Pro Val Asn Ala Thr Glu Asp  
 195 200 205

Pro Ser Ser Gly Tyr Tyr Ser Thr Thr Ile Arg Tyr Gln Ala Thr Gly  
 210 215 220

Phe Gly Thr Asn Glu Thr Glu Tyr Leu Phe Glu Val Asp Asn Leu Thr  
 225 230 235 240

Tyr Val Gln Leu Glu Ser Arg Phe Thr Pro Gln Phe Leu Leu Gln Leu  
 245 250 255

Asn Glu Thr Ile Tyr Thr Ser Gly Lys Arg Ser Asn Thr Thr Gly Lys  
 260 265 270

Leu Ile Trp Lys Val Asn Pro Glu Ile Asp Thr Thr Ile Gly Glu Trp  
 275 280 285

Ala Phe Trp Glu Thr Lys Lys Asn Leu Thr Arg Lys Ile Arg Ser Glu  
 290 295 300

Glu Leu Ser Phe Thr Val Val Ser Asn Gly Ala Lys Asn Ile Ser Gly  
 305 310 315 320

Gln Ser Pro Ala Arg Thr Ser Ser Asp Pro Gly Thr Asn Thr Thr Thr  
 325 330 335

Glu Asp His Lys Ile Met Ala Ser Glu Asn Ser Ser Ala Met Val Gln  
 340 345 350

Val His Ser Gln Gly Arg Glu Ala Ala Val Ser His Leu Thr Thr Leu  
 355 360 365

Ala Thr Ile Ser Thr Ser Pro Gln Ser Leu Thr Thr Lys Pro Gly Pro  
 370 375 380

Asp Asn Ser Thr His Asn Thr Pro Val Tyr Lys Leu Asp Ile Ser Glu  
 385 390 395 400

Ala Thr Gln Val Glu Gln His His Arg Arg Thr Asp Asn Asp Ser Thr  
 405 410 415

Ala Ser Asp Thr Pro Ser Ala Thr Thr Ala Ala Gly Pro Pro Lys Ala  
 420 425 430

Glu Asn Thr Asn Thr Ser Lys Ser Thr Asp Phe Leu Asp Pro Ala Thr  
 435 440 445

Thr Thr Ser Pro Gln Asn His Ser Glu Thr Ala Gly Asn Asn Asn Thr  
 450 455 460

His His Gln Asp Thr Gly Glu Glu Ser Ala Ser Ser Gly Lys Leu Gly  
 465 470 475 480

Leu Ile Thr Asn Thr Ile Ala Gly Val Ala Gly Leu Ile Thr Gly Gly  
 485 490 495

Arg Arg Thr Arg Arg Glu Ala Ile Val Asn Ala Gln Pro Lys Cys Asn  
 500 505 510

Pro Asn Leu His Tyr Trp Thr Thr Gln Asp Glu Gly Ala Ala Ile Gly  
 515 520 525

Leu Ala Trp Ile Pro Tyr Phe Gly Pro Ala Ala Glu Gly Ile Tyr Ile  
 530 535 540

Glu Gly Leu Met His Asn Gln Asp Gly Leu Ile Cys Gly Leu Arg Gln  
 545 550 555 560

Leu Ala Asn Glu Thr Thr Gln Ala Leu Gln Leu Phe Leu Arg Ala Thr  
 565 570 575

Thr Glu Leu Arg Thr Phe Ser Ile Leu Asn Arg Lys Ala Ile Asp Phe  
 580 585 590

Leu Leu Gln Arg Trp Gly Gly Thr Cys His Ile Leu Gly Pro Asp Cys  
 595 600 605

Cys Ile Glu Pro His Asp Trp Thr Lys Asn Ile Thr Asp Lys Ile Asp  
 610 615 620

Gln Ile Ile His Asp Phe Val Asp Lys Thr Leu Pro Asp Gln Gly Asp  
 625 630 635 640

Asn Asp Asn Trp Trp Thr Gly Trp Arg Gln Trp Ile Pro Ala Gly Ile  
 645 650 655

Gly Val Thr Gly Val Ile Ile Ala Val Ile Ala Leu Phe Cys Ile Cys  
 660 665 670

Lys Phe Val Phe  
 675

<210> 2  
 <211> 364  
 <212> PRT  
 <213> Ebola virus

<400> 2

Met Gly Val Thr Gly Ile Leu Gln Leu Pro Arg Asp Arg Phe Lys Arg  
 1 5 10 15

Thr Ser Phe Phe Leu Trp Val Ile Ile Leu Phe Gln Arg Thr Phe Ser  
 20 25 30

Ile Pro Leu Gly Val Ile His Asn Ser Thr Leu Gln Val Ser Asp Val  
 35 40 45

Asp Lys Leu Val Cys Arg Asp Lys Leu Ser Ser Thr Asn Gln Leu Arg  
 50 55 60

Ser Val Gly Leu Asn Leu Glu Gly Asn Gly Val Ala Thr Asp Val Pro  
 65 70 75 80

Ser Ala Thr Lys Arg Trp Gly Phe Arg Ser Gly Val Pro Pro Lys Val  
 85 90 95

Val Asn Tyr Glu Ala Gly Glu Trp Ala Glu Asn Cys Tyr Asn Leu Glu  
 100 105 110

Ile Lys Lys Pro Asp Gly Ser Glu Cys Leu Pro Ala Ala Pro Asp Gly  
 115 120 125

Ile Arg Gly Phe Pro Arg Cys Arg Tyr Val His Lys Val Ser Gly Thr  
 130 135 140

Gly Pro Cys Ala Gly Asp Phe Ala Phe His Lys Glu Gly Ala Phe Phe  
 145 150 155 160

Leu Tyr Asp Arg Leu Ala Ser Thr Val Ile Tyr Arg Gly Thr Thr Phe  
 165 170 175

Ala Glu Gly Val Val Ala Phe Leu Ile Leu Pro Gln Ala Lys Lys Asp  
 180 185 190

Phe Phe Ser Ser His Pro Leu Arg Glu Pro Val Asn Ala Thr Glu Asp  
 195 200 205

Pro Ser Ser Gly Tyr Tyr Ser Thr Thr Ile Arg Tyr Gln Ala Thr Gly  
 210 215 220

Phe Gly Thr Asn Glu Thr Glu Tyr Leu Phe Glu Val Asp Asn Leu Thr  
 225 230 235 240

Tyr Val Gln Leu Glu Ser Arg Phe Thr Pro Gln Phe Leu Leu Gln Leu  
 245 250 255

Asn Glu Thr Ile Tyr Thr Ser Gly Lys Arg Ser Asn Thr Thr Gly Lys  
 260 265 270

Leu Ile Trp Lys Val Asn Pro Glu Ile Asp Thr Thr Ile Gly Glu Trp  
 275 280 285

Ala Phe Trp Glu Thr Lys Lys Thr Ser Leu Glu Lys Phe Ala Val Lys  
 290 295 300

Ser Cys Leu Ser Gln Leu Tyr Gln Thr Glu Pro Lys Thr Ser Val Val  
 305 310 315 320

Arg Val Arg Arg Glu Leu Leu Pro Thr Gln Gly Pro Thr Gln Gln Leu  
 325 330 335

Lys Thr Thr Lys Ser Trp Leu Gln Lys Ile Pro Leu Gln Trp Phe Lys

340

345

350

Cys Thr Val Lys Glu Gly Lys Leu Gln Cys Arg Ile  
 355 360

<210> 3  
 <211> 511  
 <212> PRT  
 <213> Vesicular stomatitis virus

<400> 3

Met Lys Cys Leu Leu Tyr Leu Ala Phe Leu Phe Ile Gly Val Asn Cys  
 1 5 10 15

Lys Phe Thr Ile Val Phe Pro His Asn Gln Lys Gly Asn Trp Lys Asn  
 20 25 30

Val Pro Ser Asn Tyr His Tyr Cys Pro Ser Ser Ser Asp Leu Asn Trp  
 35 40 45

His Asn Asp Leu Ile Gly Thr Ala Leu Gln Val Lys Met Pro Lys Ser  
 50 55 60

His Lys Ala Ile Gln Ala Asp Gly Trp Met Cys His Ala Ser Lys Trp  
 65 70 75 80

Val Thr Thr Cys Asp Phe Arg Trp Tyr Gly Pro Lys Tyr Ile Thr His  
 85 90 95

Ser Ile Arg Ser Phe Thr Pro Ser Val Glu Gln Cys Lys Glu Ser Ile  
 100 105 110

Glu Gln Thr Lys Gln Gly Thr Trp Leu Asn Pro Gly Phe Pro Pro Gln  
 115 120 125

Ser Cys Gly Tyr Ala Thr Val Thr Asp Ala Glu Ala Val Ile Val Gln  
 130 135 140

Val Thr Pro His His Val Leu Val Asp Glu Tyr Thr Gly Glu Trp Val  
 145 150 155 160

Asp Ser Gln Phe Ile Asn Gly Lys Cys Ser Asn Tyr Ile Cys Pro Thr  
 165 170 175

Val His Asn Ser Thr Thr Trp His Ser Asp Tyr Lys Val Lys Gly Leu



180	185	190
Cys Asp Ser Asn Leu Ile Ser Met Asp Ile Thr Phe Phe Ser Glu Asp 195 200 205		
Gly Glu Leu Ser Ser Leu Gly Lys Glu Gly Thr Gly Phe Arg Ser Asn 210 215 220		
Tyr Phe Ala Tyr Glu Thr Gly Gly Lys Ala Cys Lys Met Gln Tyr Cys 225 230 235 240		
Lys His Trp Gly Val Arg Leu Pro Ser Gly Val Trp Phe Glu Met Ala 245 250 255		
Asp Lys Asp Leu Phe Ala Ala Ala Arg Phe Pro Glu Cys Pro Glu Gly 260 265 270		
Ser Ser Ile Ser Ala Pro Ser Gln Thr Ser Val Asp Val Ser Leu Ile 275 280 285		
Gln Asp Val Glu Arg Ile Leu Asp Tyr Ser Leu Cys Gln Glu Thr Trp 290 295 300		
Ser Lys Ile Arg Ala Gly Leu Pro Ile Ser Pro Val Asp Leu Ser Tyr 305 310 315 320		
Leu Ala Pro Lys Asn Pro Gly Thr Gly Pro Ala Phe Thr Ile Ile Asn 325 330 335		
Gly Thr Leu Lys Tyr Phe Glu Thr Arg Tyr Ile Arg Val Asp Ile Ala 340 345 350		
Ala Pro Ile Leu Ser Arg Met Val Gly Met Ile Ser Gly Thr Thr Thr 355 360 365		
Glu Arg Glu Leu Trp Asp Asp Trp Ala Pro Tyr Glu Asp Val Glu Ile 370 375 380		
Gly Pro Asn Gly Val Leu Arg Thr Ser Ser Gly Tyr Lys Phe Pro Leu 385 390 395 400		
Tyr Met Ile Gly His Gly Met Leu Asp Ser Asp Leu His Leu Ser Ser 405 410 415		

Lys Ala Gln Val Phe Glu His Pro His Ile Gln Asp Ala Ala Ser Gln  
 420 425 430

Leu Pro Asp Asp Glu Ser Leu Phe Phe Gly Asp Thr Gly Leu Ser Lys  
 435 440 445

Asn Pro Ile Glu Leu Val Glu Gly Trp Phe Ser Ser Trp Lys Ser Ser  
 450 455 460

Ile Ala Ser Phe Phe Phe Ile Ile Gly Leu Ile Ile Gly Leu Phe Leu  
 465 470 475 480

Val Leu Arg Val Gly Ile His Leu Cys Ile Lys Leu Lys His Thr Lys  
 485 490 495

Lys Arg Gln Ile Tyr Thr Asp Ile Glu Met Asn Arg Leu Gly Lys  
 500 505 510

<210> 4  
 <211> 147  
 <212> DNA  
 <213> Vesicular stomatitis virus

<400> 4  
 agctctattg cctctttttt ctttatcata gggttaatca ttggactatt cttggttctc 60  
 cgagttggta tccatctttg cattaaatta aagcacacca agaaaagaca gatttatata 120  
 gacatagaga tgaaccgact tggaaag 147

<210> 5  
 <211> 126  
 <212> DNA  
 <213> Vesicular stomatitis virus

<400> 5  
 ttcgaacatc ctcacattca agacgctgct tcgcaacttc ctgatgatga gagtttattt 60  
 tttggtgata ctgggctatc caaaaatcca atcgagcttg tagaagggttg gttcagtagt 120  
 tggaaa 126

<210> 6  
 <211> 654  
 <212> PRT  
 <213> Murine leukemia virus

<400> 6

Met Ala Arg Ser Thr Leu Ser Lys Pro Pro Lys Asp Lys Ile Asn Pro  
 1 5 10 15

Trp Lys Ser Leu Met Val Met Gly Val Leu Leu Arg Val Gly Met Ala  
 20 25 30

Glu Ser Pro His Gln Val Phe Asn Val Thr Trp Arg Val Thr Asn Leu  
 35 40 45

Met Thr Gly Arg Thr Ala Asn Ala Thr Ser Leu Leu Gly Thr Val Gln  
 50 55 60

Asp Ala Phe Pro Arg Leu Tyr Phe Asp Leu Cys Asp Leu Val Gly Glu  
 65 70 75 80

Glu Trp Asp Pro Ser Asp Gln Glu Pro Tyr Val Gly Tyr Gly Cys Lys  
 85 90 95

Tyr Pro Ala Gly Arg Gln Arg Thr Arg Thr Phe Asp Phe Tyr Val Cys  
 100 105 110

Pro Gly His Thr Val Lys Ser Gly Cys Gly Gly Pro Gly Glu Gly Tyr  
 115 120 125

Cys Gly Lys Trp Gly Cys Glu Thr Thr Gly Gln Ala Tyr Trp Lys Pro  
 130 135 140

Thr Ser Ser Trp Asp Leu Ile Ser Leu Lys Arg Gly Asn Thr Pro Trp  
 145 150 155 160

Asp Thr Gly Cys Ser Lys Val Ala Cys Gly Pro Cys Tyr Asp Leu Ser  
 165 170 175

Lys Val Ser Asn Ser Phe Gln Gly Ala Thr Arg Gly Gly Arg Cys Asn  
 180 185 190

Pro Leu Val Leu Glu Phe Thr Asp Ala Gly Lys Lys Ala Asn Trp Asp  
 195 200 205

Gly Pro Lys Ser Trp Gly Leu Arg Leu Tyr Arg Thr Gly Thr Asp Pro  
 210 215 220

Ile Thr Met Phe Ser Leu Thr Arg Gln Val Leu Asn Val Gly Pro Arg  
 225 230 235 240

Val Pro Ile Gly Pro Asn Pro Val Leu Pro Asp Gln Arg Leu Pro Ser

245	250	255
Ser Pro Val Glu Ala Ile Pro Ala Pro Gln Pro Pro Ser Pro Leu Asn 260 265 270		
Thr Ser Tyr Pro Pro Ser Thr Ala Ser Thr Pro Ser Thr Ser Pro Thr 275 280 285		
Ser Pro Ser Ala Pro Gln Pro Pro Pro Gly Thr Gly Asp Arg Leu Leu 290 295 300		
Ala Leu Val Lys Gly Ala Tyr Gln Ala Leu Asn Leu Thr Asn Pro Asp 305 310 315 320		
Lys Thr Gln Glu Cys Trp Leu Cys Leu Val Ser Gly Pro Pro Tyr Tyr 325 330 335		
Glu Gly Val Ala Val Val Gly Thr Tyr Thr Asn His Ser Thr Ala Pro 340 345 350		
Ala Asn Cys Thr Ala Thr Ser Gln His Lys Leu Thr Leu Ser Glu Val 355 360 365		
Thr Gly Gln Gly Leu Cys Met Gly Ala Val Pro Lys Thr His Gln Ala 370 375 380		
Leu Cys Asn Thr Thr Gln Ser Ala Gly Ser Gly Ser Tyr Tyr Leu Ala 385 390 395 400		
Ala Pro Thr Gly Thr Met Trp Ala Cys Ser Thr Gly Leu Thr Pro Cys 405 410 415		
Leu Ser Thr Thr Val Leu Asn Leu Thr Thr Asp Tyr Cys Val Leu Val 420 425 430		
Glu Leu Trp Pro Arg Val Ile Tyr His Ser Pro Asp Tyr Met Tyr Gly 435 440 445		
Gln Leu Glu Gln Arg Thr Lys Tyr Lys Arg Glu Pro Val Ser Leu Thr 450 455 460		
Leu Ala Leu Leu Leu Gly Gly Leu Thr Met Gly Gly Ile Ala Ala Gly 465 470 475 480		

Ile Gly Thr Gly Thr Thr Ala Leu Ile Lys Thr Gln Gln Phe Glu Gln  
 485 490 495

Leu His Ala Ala Ile Gln Thr Asp Leu Asn Glu Val Glu Lys Ser Ile  
 500 505 510

Thr Asn Leu Glu Lys Ser Leu Thr Ser Leu Ser Glu Val Val Leu Gln  
 515 520 525

Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Lys Glu Gly Gly Leu Cys  
 530 535 540

Ala Ala Leu Lys Glu Glu Cys Cys Phe Tyr Ala Asp His Thr Gly Leu  
 545 550 555 560

Val Arg Asp Ser Met Ala Lys Leu Arg Glu Arg Leu Asn Gln Arg Gln  
 565 570 575

Lys Leu Phe Glu Ser Gly Gln Gly Trp Phe Glu Gly Leu Phe Asn Arg  
 580 585 590

Ser Pro Trp Phe Thr Thr Leu Ile Ser Thr Ile Met Gly Pro Leu Ile  
 595 600 605

Val Leu Leu Leu Ile Leu Leu Phe Gly Pro Cys Ile Leu Asn Arg Leu  
 610 615 620

Val Gln Phe Val Lys Asp Arg Ile Ser Val Val Gln Ala Leu Val Leu  
 625 630 635 640

Thr Gln Gln Tyr His Gln Leu Lys Pro Ile Glu Tyr Glu Pro  
 645 650

<210> 7

<211> 96

<212> DNA

<213> Murine leukemia virus

<400> 7

cgattagtc aatttggttaa agacaggata tcagtgggtcc aggctctagt tttgactcaa 60

caatatcacc agctgaagcc tatagagtac gagcca 96

<210> 8

<211> 856

<212> PRT

<213> Human immunodeficiency virus type 1

&lt;400&gt; 8

Met Arg Val Lys Glu Lys Tyr Gln His Leu Trp Arg Trp Gly Trp Arg  
 1 5 10 15

Trp Gly Thr Met Leu Leu Gly Met Leu Met Ile Cys Ser Ala Thr Glu  
 20 25 30

Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala  
 35 40 45

Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu  
 50 55 60

Val His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn  
 65 70 75 80

Pro Gln Glu Val Val Leu Val Asn Val Thr Glu Asn Phe Asn Met Trp  
 85 90 95

Lys Asn Asp Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp  
 100 105 110

Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Ser  
 115 120 125

Leu Lys Cys Thr Asp Leu Lys Asn Asp Thr Asn Thr Asn Ser Ser Ser  
 130 135 140

Gly Arg Met Ile Met Glu Lys Gly Glu Ile Lys Asn Cys Ser Phe Asn  
 145 150 155 160

Ile Ser Thr Ser Ile Arg Gly Lys Val Gln Lys Glu Tyr Ala Phe Phe  
 165 170 175

Tyr Lys Leu Asp Ile Ile Pro Ile Asp Asn Asp Thr Thr Ser Tyr Lys  
 180 185 190

Leu Thr Ser Cys Asn Thr Ser Val Ile Thr Gln Ala Cys Pro Lys Val  
 195 200 205

Ser Phe Glu Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Phe Ala  
 210 215 220

Ile Leu Lys Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr  
 225 230 235 240  
 Asn Val Ser Thr Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser  
 245 250 255  
 Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu Val Val Ile  
 260 265 270  
 Arg Ser Val Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile Val Gln Leu  
 275 280 285  
 Asn Thr Ser Val Glu Ile Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg  
 290 295 300  
 Lys Arg Ile Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile  
 305 310 315 320  
 Gly Lys Ile Gly Asn Met Arg Gln Ala His Cys Asn Ile Ser Arg Ala  
 325 330 335  
 Lys Trp Asn Asn Thr Leu Lys Gln Ile Ala Ser Lys Leu Arg Glu Gln  
 340 345 350  
 Phe Gly Asn Asn Lys Thr Ile Ile Phe Lys Gln Ser Ser Gly Gly Asp  
 355 360 365  
 Pro Glu Ile Val Thr His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr  
 370 375 380  
 Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp  
 385 390 395 400  
 Ser Thr Glu Gly Ser Asn Asn Thr Glu Gly Ser Asp Thr Ile Thr Leu  
 405 410 415  
 Pro Cys Arg Ile Lys Gln Ile Ile Asn Met Trp Gln Lys Val Gly Lys  
 420 425 430  
 Ala Met Tyr Ala Pro Pro Ile Ser Gly Gln Ile Arg Cys Ser Ser Asn  
 435 440 445  
 Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Asn Ser Asn Asn Glu  
 450 455 460

Ser Glu Ile Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg  
 465 470 475 480

Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val  
 485 490 495

Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln Arg Glu Lys Arg Ala  
 500 505 510

Val Gly Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly Ser  
 515 520 525

Thr Met Gly Ala Ala Ser Met Thr Leu Thr Val Gln Ala Arg Gln Leu  
 530 535 540

Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile Glu  
 545 550 555 560

Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu  
 565 570 575

Gln Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln Leu  
 580 585 590

Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Ala Val  
 595 600 605

Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Glu Gln Ile Trp Asn  
 610 615 620

His Thr Thr Trp Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser  
 625 630 635 640

Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln Glu Lys Asn  
 645 650 655

Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp  
 660 665 670

Phe Asn Ile Thr Asn Trp Leu Trp Tyr Ile Lys Leu Phe Ile Met Ile  
 675 680 685

Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe Ala Val Leu Ser Ile  
 690 695 700



Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr His  
705 710 715 720

Leu Pro Thr Pro Arg Gly Pro Asp Arg Pro Glu Gly Ile Glu Glu Glu  
725 730 735

Gly Gly Glu Arg Asp Arg Asp Arg Ser Ile Arg Leu Val Asn Gly Ser  
740 745 750

Leu Ala Leu Ile Trp Asp Asp Leu Arg Ser Leu Cys Leu Phe Ser Tyr  
755 760 765

His Arg Leu Arg Asp Leu Leu Leu Ile Val Thr Arg Ile Val Glu Leu  
770 775 780

Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr Trp Trp Asn Leu Leu  
785 790 795 800

Gln Tyr Trp Ser Gln Glu Leu Lys Asn Ser Ala Val Ser Leu Leu Asn  
805 810 815

Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val  
820 825 830

Val Gln Gly Ala Cys Arg Ala Ile Arg His Ile Pro Arg Arg Ile Arg  
835 840 845

Gln Gly Leu Glu Arg Ile Leu Leu  
850 855

<210> 9  
<211> 498  
<212> PRT  
<213> Lymphocytic choriomeningitis virus

<400> 9

Met Gly Gln Ile Val Thr Met Phe Glu Ala Leu Pro His Ile Ile Asp  
1 5 10 15

Glu Val Ile Asn Ile Val Ile Ile Val Leu Ile Val Ile Thr Gly Ile  
20 25 30

Lys Ala Val Tyr Asn Phe Ala Thr Cys Gly Ile Phe Ala Leu Ile Ser  
35 40 45

Phe Leu Leu Leu Ala Gly Arg Ser Cys Gly Met Tyr Gly Leu Lys Gly  
 50 55 60

Pro Asp Ile Tyr Lys Gly Val Tyr Gln Phe Lys Ser Val Glu Phe Asp  
 65 70 75 80

Met Ser His Leu Asn Leu Thr Met Pro Asn Ala Cys Ser Ala Asn Asn  
 85 90 95

Ser His His Tyr Ile Ser Met Gly Thr Ser Gly Leu Glu Leu Thr Phe  
 100 105 110

Thr Asn Asp Ser Ile Ile Ser His Asn Phe Cys Asn Leu Thr Ser Ala  
 115 120 125

Phe Asn Lys Lys Thr Phe Asp His Thr Leu Met Ser Ile Val Ser Ser  
 130 135 140

Leu His Leu Ser Ile Arg Gly Asn Ser Asn Tyr Lys Ala Val Ser Cys  
 145 150 155 160

Asp Phe Asn Asn Gly Ile Thr Ile Gln Tyr Asn Leu Thr Phe Ser Asp  
 165 170 175

Ala Gln Ser Ala Gln Ser Gln Cys Arg Thr Phe Arg Gly Arg Val Leu  
 180 185 190

Asp Met Phe Arg Thr Ala Phe Gly Gly Lys Tyr Met Arg Ser Gly Trp  
 195 200 205

Gly Trp Thr Gly Ser Asp Gly Lys Thr Thr Trp Cys Ser Gln Thr Ser  
 210 215 220

Tyr Gln Tyr Leu Ile Ile Gln Asn Arg Thr Trp Glu Asn His Cys Thr  
 225 230 235 240

Tyr Ala Gly Pro Phe Gly Met Ser Arg Ile Leu Leu Ser Gln Glu Lys  
 245 250 255

Thr Lys Phe Phe Thr Arg Arg Leu Ala Gly Thr Phe Thr Trp Thr Leu  
 260 265 270

Ser Asp Ser Ser Gly Val Glu Asn Pro Gly Gly Tyr Cys Leu Thr Lys

275	280	285
Trp Met Ile Leu Ala Ala Glu Leu Lys Cys Phe Gly Asn Thr Ala Val		
290	295	300
Ala Lys Cys Asn Val Asn His Asp Ala Glu Phe Cys Asp Met Leu Arg		
305	310	315
Leu Ile Asp Tyr Asn Lys Ala Ala Leu Ser Lys Phe Lys Glu Asp Val		
325	330	335
Glu Ser Ala Leu His Leu Phe Lys Thr Thr Val Asn Ser Leu Ile Ser		
340	345	350
Asp Gln Leu Leu Met Arg Asn His Leu Arg Asp Leu Met Gly Val Pro		
355	360	365
Tyr Cys Asn Tyr Ser Lys Phe Trp Tyr Leu Glu His Ala Lys Thr Gly		
370	375	380
Glu Thr Ser Val Pro Lys Cys Trp Leu Val Thr Asn Gly Ser Tyr Leu		
385	390	395
Asn Glu Thr His Phe Ser Asp Gln Ile Glu Gln Glu Ala Asp Asn Met		
405	410	415
Ile Thr Glu Met Leu Arg Lys Asp Tyr Ile Lys Arg Gln Gly Ser Thr		
420	425	430
Pro Leu Ala Leu Met Asp Leu Leu Met Phe Ser Thr Ser Ala Tyr Leu		
435	440	445
Val Ser Ile Phe Leu His Leu Val Lys Ile Pro Thr His Arg His Ile		
450	455	460
Lys Gly Gly Ser Cys Pro Lys Pro His Arg Leu Thr Asn Lys Gly Ile		
465	470	475
Cys Ser Cys Gly Ala Phe Lys Val Pro Gly Val Lys Thr Val Trp Lys		
485	490	495
Arg Arg		

<210> 10  
 <211> 180  
 <212> DNA  
 <213> Lymphocytic choriomeningitis virus

<400> 10  
 cttttgatgt tttcaacatc agcatatcta atcagcatct ttctgcatct tgtgaagata 60  
 ccaacacata gacacataaa gggcggttca tgtccaaagc cacaccgctt gaccaacaag 120  
 gggatctgta gttgtggtgc attcaagggtg cctggtgtaa aaactatctg gaaaagacgc 180

<210> 11  
 <211> 31  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 11  
 aagatccgc caccatgggc gttacaggaa t 31

<210> 12  
 <211> 24  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 12  
 gtcacgacaa actagtttgt cgac 24

<210> 13  
 <211> 25  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 13  
 gggaattctt actttccaag tcggt 25

<210> 14  
 <211> 29  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 14  
 ggatggagaa gctctattgc ctctttttt 29

<210> 15  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 15  
ggatggagaa ttgcctcttt tttcttt

27

<210> 16  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 16  
ggatggagat ggaaaagctc tattgcc

27

<210> 17  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 17  
ggatggagat ccaaaaatcc aatcgag

27

<210> 18  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 18  
ggatggagat tttttggtga tactggg

27

<210> 19  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 19

tgtatatgcc gagttggtat ccatctt

27

<210> 20  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 20  
tttgtctttc gagttggtat ccatctt

27

<210> 21  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 21  
ggatggagac ttttgatggt ttcaaca

27

<210> 22  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 22  
gggaattctc agcgtctttt ccagatag

28

<210> 23  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 23  
tgtatatgcc gattagtcca atttggtta

28

<210> 24  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 24  
gggaattcta tagagcctgg accactgat 29

<210> 25  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 25  
gggaattcta tggctcgtac tctataggg 29

<210> 26  
<211> 17  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 26  
tgggaccgga ctgctgt 17

<210> 27  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 27  
aatagagctt ctccatcctg tccacca 27

<210> 28  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 28  
agaggcaatt ctccatcctg tccacca 27

<210> 29  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 29  
gcttttccat ctccatcctg tccacca 27

<210> 30  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 30  
atttttggat ctccatcctg tccacca 27

<210> 31  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 31  
accaaaaaat ctccatcctg tccacca 27

<210> 32  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 32  
accaactcgg catatacaga ataaagcg 28

<210> 33  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 33  
accaactcga aagacaaatt tgcatat 27

<210> 34  
<211> 28  
<212> DNA  
<213> Artificial

<220>



<223> primer

<400> 34

gactaatcgg catatacaga ataaagcg

28

<210> 35

<211> 27

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 35

catcaaaagt ctccatcctg tccacca

27

<210> 36

<211> 28

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 36

tgaattccta gcatatacag aataaagc

28

<210> 37

<211> 30

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 37

tttttcatga tttttttggt gatactgggc

30

<210> 38

<211> 31

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 38

tttttggcca acttttttgg tgatactggg c

31

<210> 39

<211> 25

<212> DNA

<213> Artificial

<220>  
<223> primer

<400> 39  
gggaattctt actttccaag tcggt 25

<210> 40  
<211> 17  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 40  
ggacccgtct agtggct 17

<210> 41  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 41  
agttcttctt gttagatgcg aactgcag 29

<210> 42  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 42  
aattgcttct gttagatgcg aactgcag 29

<210> 43  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 43  
tgtgatcagt gtggcaaggg ttgttag 27

<210> 44  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> primer  
  
<400> 44  
cgagttcttc ttacaactgt gaaagacaa 29  
  
<210> 45  
<211> 27  
<212> DNA  
<213> Artificial  
  
<220>  
<223> primer  
  
<400> 45  
agttcttctc tccccgattg ttgtatc 27  
  
<210> 46  
<211> 27  
<212> DNA  
<213> Artificial  
  
<220>  
<223> primer  
  
<400> 46  
agttcttctg gggttgacct tccaaat 27  
  
<210> 47  
<211> 27  
<212> DNA  
<213> Artificial  
  
<220>  
<223> primer  
  
<400> 47  
agttcttctg ctctttttcc cacttgt 27  
  
<210> 48  
<211> 27  
<212> DNA  
<213> Artificial  
  
<220>  
<223> primer  
  
<400> 48  
agttcttctc tcattcagct ggagcag 27  
  
<210> 49  
<211> 27  
<212> DNA

<213> Artificial

<220>

<223> primer

<400> 49

agttcttctg gtcaaattgt caacctc

27

<210> 50

<211> 27

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 50

agttcttctt ccaaaaccgg tagcctg

27

<210> 51

<211> 29

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 51

aatagagctt tgtctccatc ctgtccacc

29

<210> 52

<211> 27

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 52

catctaacaa gaagaactcg aagagaa

27

<210> 53

<211> 28

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 53

catctaacag aagcaattgt caatgctc

28

<210> 54

<211> 27

<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 54  
cttgccacac tgatcacagg cgggaga

27

<210> 55  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 55  
cacagttgta agaagaactc gaagagaa

28

<210> 56  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 56  
atcggggaga gaagaactcg aagagaa

27

<210> 57  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 57  
gtcaacccca gaagaactcg aagagaa

27

<210> 58  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 58  
aaaaggagca gaagaactcg aagagaa

27

<210> 59

<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 59  
ctgaatgaga gaagaactcg aagagaa 27

<210> 60  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 60  
aatttgacca gaagaactcg aagagaa 27

<210> 61  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 61  
ggttttggaa gaagaactcg aagagaa 27

<210> 62  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 62  
tttctcgagt tttctcacta ggagact 27

<210> 63  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 63  
tttctcgagt aggagacttg caggcac 27

<210> 64  
 <211> 17  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 64  
 gcaacagctg tattccc

17

<210> 65  
 <211> 25  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 65  
 aattgaacca tctcgagtag cacco

25

<210> 66  
 <211> 33  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 66  
 cccactccat tccggactcg ggattccacc tga

33

<210> 67  
 <211> 11  
 <212> PRT  
 <213> Artificial

<220>  
 <223> epitope

<400> 67

Glx Tyr Gln Val Asn Asn Leu Glu Glu Ile Cys  
 1 5 10

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number  
**WO 2003/092582 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 39/52**, C12N 21/00, 21/02, 15/83, 15/86, 15/867
- (74) Agents: **KODROFF, Cathy, A.** et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).
- (21) International Application Number:  
PCT/US2003/011494
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 28 April 2003 (28.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/376,480 30 April 2002 (30.04.2002) US  
60/385,704 4 June 2002 (04.06.2002) US  
60/427,752 20 November 2002 (20.11.2002) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-3147 (US).
- Published:  
— with international search report
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **WILSON, James, M.** [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US). **MEDINA, Maria, Fe, C.** [CA/US]; 2200 Ben Franklin Parkway, W401, Philadelphia, PA 19130 (US). **KOBINGER, Gary** [CA/US]; 2049B Bainbridge Street, Philadelphia, PA 19146 (US).
- (88) Date of publication of the international search report:  
1 July 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CHIMERIC EBOLA VIRUS ENVELOPES AND USES THEREFOR

(57) Abstract: Chimeric ebola envelope proteins and uses therefore are described. The chimeric envelope proteins are useful for packaging viral vectors and targeting these vectors in vivo, to lung cells following intratracheal delivery or for delivery of molecules, ex vivo, to macrophages and dendritic cells. In another aspect, also provided herein are immunogenic compositions which contain ebola envelope proteins and uses thereof.



WO 2003/092582 A3



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/11494

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39-52; C12N 21/00, 21/02, 15/83, 15/86, 15/867

US CL : 424/184.1, 192.1, 199.1, 204.1, 205.1; 435/69.1, 91.1, 91.41, 91.42, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 192.1, 199.1, 204.1, 205.1; 435/69.1, 91.1, 91.41, 91.42, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KOBINGER, G.P. et al. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nature Biotechnology. March 2001, Vol. 19, pages 225-230, see entire document, especially, see EXPERIMENTAL PROTOCOL on page 229.	1-2
X,P	MACKENZIE, T.C. et al. Efficient Transduction of Liver and Muscle after in Utero Injection of Lentiviral Vectors with Different Pseudotypes. Molecular Therapy. September 2002, Vol. 6. No. 3, pages 349-358, see entire document, especially, MATERIALS AND METHODS on page 356.	1-2
X,E	MEDINA, M. F. et al. Lentivirus Vectors Pseudotyped with Minimal Filovirus Envelopes Increase gene Transfer in Murine Lung. Molecular Therapy. November 2003, Vol. 8. No. 5, pages 777-789, especially see pages 784 and 787.	1-3
A	ITO, H. et al. Mutational Analysis of the Putative Fusion Domain of Ebola Virus Glycoprotein. J. Virol. October 1999, Vol. 73. No. 10, pages 8907-8912.	1-6, 7
A	WATANABE, S. et al. Functional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein. J. Virol. November 2000, Vol. 74. No. 21, pages 10194-10201.	1-6, 17

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

07 February 2004 (07.02.2004)

Date of mailing of the international search report

02 APR 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Bao Qun Li

Telephone No. 703-308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/11494

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 7-16 and 18-48  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
- Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

PCT/US03/104

**Continuation of B. FIELDS SEARCHED Item 3:**

**CAPLUS, MEDLINE, WEST, SEQUESE SEARCH.**

Search terms: Ebola glycoprotein, Ebola chimeric envelope, Filovirus, pseudotyped viral vector, recombinant Ebola envelope protein

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number  
**WO 2003/092582 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 39/52**,  
C12N 21/00, 21/02, 15/83, 15/86, 15/867
- (21) International Application Number:  
PCT/US2003/011494
- (22) International Filing Date: 28 April 2003 (28.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/376,480 30 April 2002 (30.04.2002) US  
60/385,704 4 June 2002 (04.06.2002) US  
60/427,752 20 November 2002 (20.11.2002) US
- (71) Applicant (*for all designated States except US*): **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-3147 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **WILSON, James, M.** [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US). **MEDINA, Maria, Fe, C.** [CA/US]; 2200 Ben Franklin Parkway, W401, Philadelphia, PA 19130 (US). **KOBINGER, Gary** [CA/US]; 2049B Bainbridge Street, Philadelphia, PA 19146 (US).
- (74) Agents: **KODROFF, Cathy, A.** et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report  
— with amended claims
- (88) Date of publication of the international search report:  
1 July 2004
- Date of publication of the amended claims: 16 December 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CHIMERIC EBOLA VIRUS ENVELOPES AND USES THEREFOR

(57) Abstract: Chimeric ebola envelope proteins and uses therefore are described. The chimeric envelope proteins are useful for packaging viral vectors and targeting these vectors in vivo, to lung cells following intratracheal delivery or for delivery of molecules, ex vivo, to macrophages and dendritic cells. In another aspect, also provided herein are immunogenic compositions which contain ebola envelope proteins and uses thereof.



WO 2003/092582 A3

**AMENDED CLAIMS**

[received by the International Bureau on 01 June 2004 (01.06.2004);  
original claims 1-24 amended; remaining claims unchanged (5 pages)]

What is claimed is:

1. A chimeric ebola envelope protein comprising a functional ebola glycoprotein binding domain fused to a heterologous amino acid sequence, wherein said chimeric protein comprises a functional deletion in an ebola envelope protein between a signal peptide and a cytoplasmic domain.
2. The chimeric ebola envelope protein according to claim 1, wherein said protein contains a wild-type ebola glycoprotein binding domain.
3. The chimeric ebola envelope protein according to claim 1, wherein said heterologous amino acid sequence is an ebola glycoprotein sequence which is non-contiguous with the binding domain in the wild-type ebola.
4. The chimeric ebola envelope protein according to claim 1, wherein said chimeric protein comprises an ebola signal peptide and an ebola binding domain having a deletion in the native ebola region between the signal peptide and the binding domain.
5. The chimeric ebola envelope protein according to claim 4, wherein said chimeric protein comprises a deletion of about 1 to 50 amino acids between the signal peptide and the binding domain.
6. The chimeric ebola envelope protein according to any of claims 1 to 3, wherein said chimeric comprises a deletion of the complete ebola signal peptide or a portion thereof.
7. The chimeric ebola envelope protein according to any of claims 1 to 3, wherein said deletion of all or a portion of the carboxy terminus of the signal peptide comprises a deletion of from about 1 to 30 amino acids.

8. The chimeric ebola envelope protein according to any of claims 1 to 7, wherein said chimeric ebola envelope comprises a deletion of all or a portion of the ebola transmembrane.

9. The chimeric ebola envelope protein according to claims 8, wherein the deletion of the ebola transmembrane comprises deletion of about 1 to 23 amino acids.

10. The chimeric ebola envelope protein according to any of claims 1 to 9, wherein said chimeric ebola envelope comprises a deletion of all or a portion of the ebola cytoplasmic domain.

11. The chimeric ebola envelope protein according to claim 10, wherein the deletion of the ebola cytoplasmic domain comprises about 1 to 3 amino acids.

12. The chimeric ebola envelope protein according to any of claims 1 to 7, said chimeric ebola envelope comprising a transmembrane domain.

13. The chimeric ebola envelope protein according to claim 12, wherein the transmembrane domain is from a heterologous protein.

14. The chimeric ebola envelope protein according to any of claims 1 to 9, wherein said protein further comprises a cytoplasmic domain.

15. The chimeric ebola envelope protein according to any of claims 1 to 12, wherein said heterologous amino acid sequence from a non-ebola protein.

16. The chimeric ebola envelope protein according to claim 15, wherein the heterologous amino acid sequence is selected from the group consisting of a

Vesicular Stomatitis Virus protein; a human immunodeficiency virus transmembrane domain; a murine leukemia virus; and a Lymphocytic Choriomeningitis virus.

17. The chimeric ebola envelope protein according to claim 1, selected from the group consisting of:

(a) NTDL1, amino acids 1 to 366 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(b) NTDL2, amino acids 1 to 366 fused to amino acids 502 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(c) NTDL3, amino acids 1 to 370 fused to amino acids 492 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(d) NTDL4, amino acids 1 to 311 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(e) NTDL5, amino acids 1 to 287 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(f) NTDL6, amino acids 1 to 279 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(g) NTDL7, amino acids 1 to 267 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(h) NTDL8, amino acids 1 to 258 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(i) NTDL9, amino acids 1 to 232 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(j) NTDL11, amino acids 1 to 231 fused to amino acids 497 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(k)  $\Delta$ N, amino acids 1 to 31 fused to 172 to 676 of the ebola glycoprotein, SEQ ID NO:1;

(l) Ebo $\Delta$ 5S, amino acids 1 to 220 of the ebola glycoprotein, SEQ ID NO:2;

(m) Ebo $\Delta$ 6S, amino acids 1 to 361 of the ebola glycoprotein, SEQ ID NO:2;

- (n) Ebo $\Delta$ 7S, amino acids 1 to 628 of the ebola glycoprotein, SEQ ID NO:2; and
- (o) Ebo $\Delta$ 8S, amino acids 1 to 311 fused to amino acids 497 to 664 of the ebola glycoprotein, SEQ ID NO:2;
- (p) V/TC, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 463 to 511 of SEQ ID NO:3;
- (q) -2aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 465 to 511 of SEQ ID NO:3;
- (r) +2aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 461 to 511 of SEQ ID NO:3;
- (s) +16aa, amino acids 1 to 672 of SEQ ID NO:1 fused amino acids 447 to 511 of SEQ ID NO:3;
- (t) +23aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 440 to 511 of SEQ ID NO:3;
- (u) +42aa, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 421 to 511 of SEQ ID NO:3;
- (v) V/C, amino acids 1 to 672 of SEQ ID NO:1 fused to amino acids 483 to 511 of SEQ ID NO:3;
- (w) V/T, amino acids 1 to 650 of SEQ ID NO:1 fused to amino acids 463 to 482 of SEQ ID NO:3;
- (x)  $\Delta$ Int, amino acids 1 to 629 of SEQ ID NO:1 fused to amino acids sequences 463 to 511 of SEQ ID NO:3;
- (y)  $\Delta$ Imm, amino acids 1 to 563 of SEQ ID NO:1 fused to amino acids 463 to 511 of SEQ ID NO:3;
- (z) VE, amino acids 180 to 350 of SEQ ID NO:1 in the VSV-G envelope, SEQ ID NO:3.
- (aa) H/TC, amino acids 1 to 650 of SEQ ID NO:1 fused to amino acids 661 to 856, SEQ ID NO:8;



(ab) M/C, amino acids 1 to 650 of SEQ ID NO:1 fused to a VSV-G transmembrane domain, 465 to 482 of SEQ ID NO:3, and an MLV-GP cytoplasmic domain, amino acids 634 to 649 of SEQ ID NO:6;

(ac) M/CR, amino acids 1 to 650 of SEQ ID NO:1 fused to a VSV-G transmembrane domain, 465 to 482 of SEQ ID NO:3, an MLV-GP cytoplasmic domain, amino acids 634 to 649 of SEQ ID NO:6, and an R peptide of MLV-GP, amino acids 650 to 665 of MLV-GP, SEQ ID NO:6;

(ad) L/TC, amino acids 1 to 650 of SEQ ID NO:1, fused to amino acids 439 to 498 of LCMV-GP, SEQ ID NO:9.

18. A nucleic acid molecule encoding a chimeric ebola protein according to any of claims 1 to 17.

19. The molecule according to claim 18, wherein said molecule is a plasmid.

20. The molecule according to claim 18, wherein said molecule is a viral vector.

21. The molecule according to claim 18, wherein said molecule is an adenoviral vector.

22. A host cell comprising a protein according to any of claims 1 to 17 or a molecule according to any of claims 18 to 21.

23. A method of inducing an immune response against ebola comprising the step of delivering to a subject a composition comprising a protein according to any of claims 1 to 17 or a molecule according to any of claims 18 to 21.

24. The method according to claim 23, wherein said composition is delivered intramuscularly.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**